



**LongRun**  
龍潤

**LONGRUN TEA GROUP COMPANY LIMITED**

(Incorporated in the Cayman Islands with limited liability)  
Stock code : 2898

Annual  
Report  
**2018**



# Contents

	Pages
CORPORATE INFORMATION	2
CHAIRMAN'S STATEMENT	3
MANAGEMENT DISCUSSION AND ANALYSIS	4
BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT	8
CORPORATE GOVERNANCE REPORT	11
REPORT OF THE DIRECTORS	22
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	34
INDEPENDENT AUDITOR'S REPORT	50
CONSOLIDATED STATEMENT OF PROFIT OR LOSS	53
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME	54
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	55
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	57
CONSOLIDATED STATEMENT OF CASH FLOWS	58
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	60
FIVE YEAR FINANCIAL SUMMARY	118

# Corporate Information

## BOARD OF DIRECTORS

### Executive Directors

Dr. Chiu Ka Leung *Chairman*  
Ms. Yeh Shu Ping *Vice-chairman and  
Chief Executive Officer*

Mr. Jiao Shaoliang  
Dr. He William (also known as Lu Pingguo)

### Independent Non-executive Directors

Mr. Lam Siu Hung  
Mr. Guo Guoqing  
Mr. Kwok Hok Lun  
Dr. Liu Zhonghua

## AUDIT COMMITTEE

Mr. Lam Siu Hung *Chairman*  
Mr. Guo Guoqing  
Mr. Kwok Hok Lun

## REMUNERATION COMMITTEE

Mr. Lam Siu Hung *Chairman*  
Dr. Chiu Ka Leung  
Ms. Yeh Shu Ping  
Mr. Guo Guoqing  
Mr. Kwok Hok Lun  
Dr. Liu Zhonghua

## NOMINATION COMMITTEE

Dr. Chiu Ka Leung *Chairman*  
Mr. Lam Siu Hung  
Mr. Guo Guoqing  
Mr. Kwok Hok Lun  
Dr. Liu Zhonghua

## INTERNAL CONTROL COMMITTEE

Mr. Lam Siu Hung *Chairman*  
Dr. Chiu Ka Leung  
Dr. He William  
Mr. Kwok Hok Lun

## COMPANY SECRETARY

Mr. Hui Pang To *FCCA, CPA*

## REGISTERED OFFICE

P.O. Box 10008, Willow House, Cricket Square,  
Grand Cayman KY1-1001, Cayman Islands.

## HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS

Room 3007A-B, Cable TV Tower,  
9 Hoi Shing Road, Tsuen Wan,  
New Territories, Hong Kong.

## AUDITOR

*Certified Public Accountants*  
Moore Stephens CPA Limited  
801-806 Silvercord, Tower 1, 30 Canton Road,  
Tsimshatsui, Kowloon, Hong Kong.

## LEGAL ADVISERS

### As to Hong Kong law:

Stevenson, Wong & Co.  
39/F, Gloucester Tower, The Landmark,  
15 Queen's Road Central, Hong Kong.

Hastings & Co.  
5/F, Gloucester Tower, The Landmark,  
11 Pedder Street, Central, Hong Kong.

## INTERNAL CONTROL ADVISER

Baker Tilly Hong Kong Risk Assurance Limited  
2nd Floor, 625 King's Road,  
North Point, Hong Kong.

## PRINCIPAL BANKERS

China Construction Bank (Asia) Corporation Limited  
Fubon Bank (Hong Kong) Limited  
The Bank of East Asia, Limited

## PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Services (Cayman Islands) Limited  
P.O. Box 10008, Willow House, Cricket Square,  
Grand Cayman KY1-1001, Cayman Islands.

## HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Tengis Limited  
Level 22, Hopewell Centre,  
183 Queen's Road East, Hong Kong.

## WEBSITE & STOCK CODE

[www.longruntea.com](http://www.longruntea.com)  
2898

# Chairman's Statement

## To our shareholders,

On behalf of the board of directors (the "Board") of Longrun Tea Group Company Limited (the "Company"), I present the annual results of the Company and its subsidiaries (the "Group") for the year ended 31 March 2018.

In 2017, although China's gross domestic product grew by 6.9%, in light of national consumption upgrade and demand changes in China, the threats posed by the rapid development of online shopping and the uncertainties of the global economy, traditional retail sales of consumer goods in China has been under tremendous pressure. It is likely that the general consumer market in China will continue to face uncertainties and remain very competitive.

Despite the uncertainties, the Group continued to focus on brand building, new product development and new distribution channel development. The Group's continuous effort in exploring new business opportunities in the direct selling area has paid off. At the end of this financial year, the Group had finalized business cooperation with one of the largest direct selling enterprises in the PRC. The Group has started to supply tea products to this new customer in the second quarter of 2018.

In addition, the Group will continue to explore opportunities to set up our own tea manufacturing base in Yunnan Province with a view to reduce reliance on our supplier.

## Appreciation

The year of 2018 will still be full of challenges. On behalf of the Board, I would like to express sincere gratitude to all shareholders and customers for their longstanding support. I would also like to thank my colleagues on the Board and the staff members of the Group for their dedication, hard work and contributions. I am confident that the Group will continue to explore and capture opportunities in the coming year and beyond.

## Chiu Ka Leung

*Chairman*

Hong Kong, 10 October 2018

# Management Discussion and Analysis

## FINANCIAL RESULTS

For the year ended 31 March 2018, the revenue of the Group decreased by approximately 34.0% to approximately HK\$81,670,000 from approximately HK\$123,690,000 for the year ended 31 March 2017. The gross profit of the Group decreased by approximately 34.3% to approximately HK\$33,512,000 for the year ended 31 March 2018 from approximately HK\$50,978,000 for the year ended 31 March 2017. The decrease in revenue is mainly attributable to (i) the continuous modification of rules and regulations by the local government on tourism related selling activities; and (ii) the effect of industry consolidation and enhanced regulation of the direct selling industry in the PRC.

Selling and distribution expenses decreased by approximately 22.9% from approximately HK\$39,448,000 for the year ended 31 March 2017 to approximately HK\$30,429,000 for the year ended 31 March 2018. Administrative expenses amounted to approximately HK\$30,946,000 for the year ended 31 March 2018, roughly remaining at the same level of approximately HK\$30,996,000 for the year ended 31 March 2017.

Other expenses decreased to approximately HK\$41,000 for the year ended 31 March 2018 from approximately HK\$17,185,000 for the year ended 31 March 2017. The decrease was mainly due to the decrease in impairment of trade receivables.

Other income decreased to approximately HK\$3,601,000 for the year ended 31 March 2018 from approximately HK\$6,416,000 for the year ended 31 March 2017. Such decrease was due to the decrease in bank interest income and various one-off government subsidies.

For the year ended 31 March 2018, the Group recorded interest income from loan receivable of approximately HK\$683,000 as compared to an interest income from loan receivable of approximately HK\$5,863,000 for the year ended 31 March 2017. Such decrease in interest income was due to the full settlement of loan receivable in the first quarter of the current financial year.

In addition, the Group did not incur any equity-settled share option expense for the year ended 31 March 2018 as compared to equity-settled share option expense of approximately HK\$6,311,000 in relation to the grant of share options to certain eligible participants under the Scheme adopted by the Company on 17 August 2012 for the year ended 31 March 2017.

Finance cost increased to approximately HK\$10,325,000 for the year ended 31 March 2018 from approximately HK\$1,652,000 for the year ended 31 March 2017. Such increase was due to the increase in effective interest expenses on convertible bonds.

Loss attributable to owners of the Company for the year ended 31 March 2018 was approximately HK\$33,902,000 (2017: loss attributable to owners of the Company of HK\$32,431,000).

Basic loss per share was HK2.34 cents for the year ended 31 March 2018 against basic loss per share of HK2.24 cents for the year ended 31 March 2017.

# Management Discussion and Analysis

## BUSINESS REVIEW

### Tea and Other Food Products Businesses

During the year under review, the Group focused on distributing tea and other food products under the well-established “Longrun (龍潤)” brand in the PRC market. The poor spending sentiment has continued to affect the consumer market in the PRC generally.

During the year under review, revenue from tea and other food products businesses was approximately HK\$77,028,000 (2017: HK\$117,861,000), accounting for approximately 94.3% (2017: 95.3%) of the Group’s total revenue.

### Tea Shops

Our traditional and convenient tea products, i.e. tea cake, loose tea leaves, tea gift set, convenient tea cups, instance tea essence and tea bags, etc., are sold in traditional tea shops. As at 31 March 2018, the Group managed a network comprising a total of over 600 tea shops (self-owned and franchised) primarily located in Mainland China. Given the competitive consumer market, the management will continue to actively manage the network with a view to enhance brand and product recognitions in the PRC.

### Mega Retail Outlets Targeting Tourists

The Group has been operating mega retail outlets in Yunnan Province targeting both domestic and international tourists travelling to Yunnan Province. The Group now operates three Mega Retail Outlets in Kunming, Yunnan Province with a gross total area over 10,000 square meters. Given the continuous modification of rules and regulations by the local government of tourism related selling activities, the operating environment of tourists related retail sales will remain very challenging in the future.

Location of Mega Retail Outlet	Highlight
Kunming International Convention and Exhibition Center (昆明國際會展中心)	A place for international exhibitions and fairs
Kunming World Horticultural Expo Garden (昆明世界園藝博覽園)	A must-see tourist attraction in Kunming
Lijiang City (麗江市)	The world famous “Old Town of Lijiang” which is a UNESCO Heritage Site

### Direct Selling

The Group started to distribute its tea products through direct selling platform in 2014. During the year under review, revenue generated from direct selling network are still affected by the consolidation and enhanced regulation of the PRC direct selling industry. However, the effect of consolidation and enhanced regulation of the PRC direct selling industry is expected to decrease over time.

### Healthcare and Pharmaceutical Business

During the year under review, revenue from healthcare and pharmaceutical business was approximately HK\$4,642,000 (2017: HK\$5,829,000), accounting for approximately 5.7% (2017: 4.7%) of the Group’s total revenue.

# Management Discussion and Analysis

## PROSPECT

Traditional retail sales of consumer goods in the PRC has been under tremendous pressure, showing a continuous slowdown. It is likely that the general consumer market in China will continue to face uncertainties and remain very competitive.

Despite the uncertainties, we will continue to focus on brand building, new product development and new distribution channel development. The Group's continuous effort in exploring new business opportunities in the direct selling area has paid off. At the end of the financial year under review, the Group had finalized business cooperation with one of the largest direct selling enterprises in the PRC. The Group has started to supply tea products to this new customer in the second quarter of 2018.

In addition, the Group will continue to explore opportunities to set up our own tea manufacturing base in Yunnan Province with a view to reduce reliance on our suppliers.

## LIQUIDITY AND FINANCIAL RESOURCES

The Group has consistently maintained sufficient working capital. As at 31 March 2018, the Group had current assets of HK\$287,745,000 (2017: HK\$339,114,000) and cash and bank balances (including cash and cash equivalents and time deposits with original maturities of more than three months) of HK\$249,649,000 (2017: HK\$142,032,000). The Group's current liabilities as at 31 March 2018 were HK\$113,050,000 (2017: HK\$83,755,000).

As at 31 March 2018, total equity was HK\$184,210,000 (2017: HK\$204,276,000). The Group had finance lease payables of HK\$467,000 as at 31 March 2018 (2017: HK\$876,000). The gearing ratio as at 31 March 2018, being the ratio of total liabilities to total equity, was 61.6% (2017: 67.3%).

On 27 January 2017, the Company issued 5.5% convertible bonds which are denominated in Hong Kong dollars with an aggregate principal amount of HK\$64,800,000 (the "Convertible Bonds") for cash to the independent third parties. The Convertible Bonds will be matured on the second anniversary of the date of issue and the conversion price is HK\$0.27 per share subject to anti-dilutive adjustments. Neither the Company nor the holders of the Convertible Bonds may demand early redemption. And the Convertible Bonds bear interests at 5.5% per annum on the outstanding principal amount and would be payable semi-annually in arrears until the Convertible Bonds are converted or matured. Unless previously converted or cancelled, upon maturity of the Convertible Bonds, the Company will pay to the holders of the Convertible Bonds an amount equal to the aggregate of 100% of the principal amount of the Convertible Bonds outstanding and interest accrued and outstanding pursuant to the terms and conditions of the Convertible Bonds. Details of the Convertible Bonds are set out in the announcements of the Company dated 11 December 2016, 19 January 2017, 27 January 2017 and 6 February 2017.

## EMPLOYEES

As at 31 March 2018, the Group had 244 employees (2017: 339 employees).

Remuneration policy and package for the Group's employees are reviewed and approved by the Board on a periodical basis. The Group remunerates its employees based on industry practice and performance of the Group and individual employees. The Group also makes available the Scheme and offers discretionary bonus to its employees.

# Management Discussion and Analysis

## CONTINGENT LIABILITIES

As at 31 March 2018, the Group did not have any significant contingent liabilities.

## EXCHANGE RISK

The Group's revenues and costs are mainly denominated in Renminbi. Since the Group entities have mostly transacted using the same currency as the functional currencies of respective Group entities, the Group does not foresee substantial risks from foreign currency exposure arising from Renminbi in this regard.

## PLEDGE OF THE GROUP'S ASSETS

As at 31 March 2018, there was no pledge of the Group's assets.

## AUDIT FINDINGS

During the performance of the audit work of the Company's consolidated financial statements for the year ended 31 March 2017, Ernst & Young ("EY"), the previous auditors of the Company identified certain inconsistencies between the cash and bank balance and the bank confirmation (the "Inconsistencies") of Yunnan Longrun Tea Technology Company Limited ("YNLRT"), a wholly-owned subsidiary of the Company (the "Audit Findings"). After the management of YNLRT was informed of the Audit Findings, a preliminary internal review (the "Review") was conducted to investigate the relevant matters. Based on the Review, the management of YNLRT noted that the accounting staff of YNLRT had failed to make appropriate entries in the accounts of YNLRT to reflect a short term bridging loan amount advanced earlier than the drawdown date as set out in an agreement (the "Loan Agreement") entered into between YNLRT and an independent third party (the "Independent Third Party") on 1 September 2016, which resulted in the Inconsistencies. The management further noted that the reasons for entering into the Loan Agreement were (i) to facilitate the Independent Third Party to invest in Longrun tea products; and (ii) to make a reasonable interest income for the Group.

Baker Tilly Hong Kong Risk Assurance Limited ("Baker Tilly") was engaged by the Company in June 2017 to perform certain agreed-upon procedures (the "AUP") to specifically address the Audit Findings. The AUP report was issued to the Board in November 2017. The Board noted the Group's internal control deficiencies identified by Baker Tilly and certain remedial measures have been adopted and implemented by the Board to address the deficiencies. Details of which were set out in the Company's announcement dated 22 June 2018.

# Biographical Details of Directors and Senior Management

## DIRECTORS

### Executive Directors

**Dr. Chiu Ka Leung**, aged 54, is the founder of the Group. He is the Chairman of the Board and of the Nomination Committee, a member of the Remuneration Committee, the Internal Control Committee and the Executive Committee of the Company and a director of certain subsidiaries of the Company. Dr. Chiu is responsible for strategic planning and overall management of business operations of the Group. Dr. Chiu graduated from 雲南省楚雄醫藥高等專科學校 (Yunnan Provincial Chuxiong Medical College) in Mainland China in 1985 with a certification in pharmacy, and has been involved in pharmaceutical research for over ten years. Prior to founding the Group, he was a pharmacist in 雲南省紅十字會醫院 (Yunnan Provincial Red Cross Hospital) in Mainland China for five years. Dr. Chiu received a master's degree in industrial economics from Graduate School of Chinese Academy of Social Sciences in 1998. In 2006, Dr. Chiu obtained a doctorate degree of corporate management from Renmin University of China, and passed the qualification examination and was awarded the title of Researcher from 雲南省中青年破格晉升高級職務評審委員會 (Evaluation Committee of Young Professionals of Yunnan Province) in the same year. He was also appraised by the provincial government in Yunnan as 雲南省有突出貢獻的優秀專業技術人才 in 2008. Dr. Chiu was awarded a 全國五一勞動獎 medal in 2009 and in 2010, he was also honoured with the title of 全國勞動模範. Dr. Chiu is the elder brother of Mr. Jiao Shaoliang (an executive director of the Company) and the brother-in-law of Dr. He William (an executive director of the Company).

**Ms. Yeh Shu Ping**, aged 71, is the Vice-chairman of the Board, the Chairman of the Executive Committee, a member of the Remuneration Committee and the Chief Executive Officer of the Company. She is also a director of various subsidiaries of the Company. She is responsible for the sales, marketing, promotion and distribution of the Group's healthcare and pharmaceutical products as well as managing the day-to-day operation of the Group's healthcare and pharmaceutical business. Ms. Yeh had worked as a nurse in hospital and clinic in Mainland China for about ten years. Before joining the Group in 1999, Ms. Yeh was a customer service manager of a hair-rebuild product company in Hong Kong. She has also worked in two health products companies in Hong Kong holding management positions in relation to customer services, sales, marketing and consulting prior to joining the Group. Ms. Yeh has extensive experience in sales and marketing of health supplement products. She is the mother of Mr. Han Ping, Joseph (the Vice-president of the Company).

**Mr. Jiao Shaoliang**, aged 44, is a member of the Executive Committee of the Company. He is also a director of certain subsidiaries of the Company. Mr. Jiao is responsible for the business development of the Group. He was awarded a diploma in clinical medicine by Kunming Medical College (now known as "Kunming Medical University") in Mainland China in 1999 and a master's degree in business administration majoring in international business by the University of La Verne, the United States in 2002. Before joining the Group in February 2002, Mr. Jiao had worked as a technician in the department of radiology of 雲南省腫瘤醫院 (Yunnan Provincial Tumor Hospital) in Mainland China for four years. Mr. Jiao is the younger brother of Dr. Chiu Ka Leung (the Chairman of the Board, an executive director and controlling shareholder of the Company) and the brother-in-law of Dr. He William (an executive director of the Company).

**Dr. He William (also known as Lu Pingguo)**, aged 46, is a member of the Executive Committee and the Internal Control Committee of the Company. He is responsible for the daily management of the tea business of the Group. Prior to joining the Group in February 2009, Dr. He was a statistical programmer and consultant in a commercial firm in Canada, who was responsible for conducting statistical analysis and preparing statistical reports. He has over ten years of experience in the statistical analysis and consulting field. Dr. He was awarded a Master of Science degree in Statistics and a Doctor of Philosophy degree in Statistics by the University of Western Ontario, Canada (now known as "Western University"). He was a member of American Statistical Association from 2005 to 2007. Dr. He is a brother-in-law of both Dr. Chiu Ka Leung (the Chairman of the Board, an executive director and controlling shareholder of the Company) and Mr. Jiao Shaoliang (an executive director of the Company).

# Biographical Details of Directors and Senior Management

## Independent Non-executive Directors

**Mr. Lam Siu Hung**, aged 59, joined the Group in September 2004. He is the Chairman of the Audit Committee, the Remuneration Committee and the Internal Control Committee, and a member of the Nomination Committee of the Company. Mr. Lam is presently a practising Certified Public Accountant and is a fellow member of the Association of Chartered Certified Accountants. Mr. Lam is also a member of the Hong Kong Institute of Certified Public Accountants. Mr. Lam has over 30 years' experience in accounting, auditing, taxation and corporate finance.

**Mr. Guo Guoqing**, aged 55, joined the Group in August 2002. He is a member of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company. Mr. Guo received his doctorate degree in economics from Renmin University of China in 1998. He is currently a professor at School of Business of Renmin University of China and a director of Marketing Research Center of China of Renmin University of China. His teaching and research interests are in the areas of marketing management.

Currently, Mr. Guo is an independent non-executive director of Livzon Pharmaceutical Group Inc., a company listed on Hong Kong Stock Exchange (stock code: 1513); and also a director of Gree Real Estate Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 600185). Besides, Mr. Guo resigned as an independent director of Wangfujing Group Co., Ltd. (previously known as Beijing Wangfujing Department Store (Group) Co., Ltd.), a company listed on the Shanghai Stock Exchange (stock code: 600859) on 28 December 2016; and resigned as the chairman of the board of supervisors of Shenzhen Takfook Technology Co., Ltd, a company listed on the Shenzhen Stock Exchange (stock code: 300134) on 20 April 2016.

**Mr. Kwok Hok Lun**, aged 41, joined the Group in October 2006. He is a member of the Audit Committee, the Remuneration Committee, the Nomination Committee and the Internal Control Committee of the Company. Mr. Kwok has been a consultant of a Hong Kong law firm (the "Law Firm"). He is responsible for the Law Firm's affairs including legal, human resources, administration and communication. Mr. Kwok was admitted as a solicitor in the High Court of the Hong Kong Special Administrative Region in 2001 and is a member of the Law Society of Hong Kong. Mr. Kwok obtained his Bachelor of Laws (with Honours) in 1998 and Postgraduate Certificate in Laws in 1999 from City University of Hong Kong. Mr. Kwok's fields of practice mainly focus on property matters, company matters and civil litigation. He also has extensive experience in giving legal advice to multinational clients in Hong Kong.

**Dr. Liu Zhonghua**, aged 53, joined the Group in January 2012. He is a member of both the Remuneration Committee and the Nomination Committee of the Company. Dr. Liu holds a doctorate degree in Analytical Chemistry of Life from the Tsinghua University. He is currently a professor and supervisor for PhD candidates at the Department of Tea Science of Hunan Agricultural University. He also acts as a director, deputy director or committee member for various tea research institutes and a number of advisory committees on tea and plants in Mainland China. Dr. Liu is a renowned Chinese expert in the field of tea science and development and exploitation of functional ingredients from botanicals. He has led a number of national key scientific research projects and programs, published papers in many academic journals and acted as a key member of the editorial committees of certain academic journals. Dr. Liu has attained distinguished achievements in the fields of chemistry of functional ingredients of tea, process and comprehensive applications of tea, theories and new technologies for process of tea and for which he has received many awards.

# Biographical Details of Directors and Senior Management

## Senior Management

**Mr. Han Ping, Joseph**, aged 48, is the Vice-president of the Company. Mr. Han is in charge of marketing and promotion of the Group's healthcare products. Mr. Han holds a bachelor's degree in business administration with a major in finance from the City University of New York, the United States. Before joining the Group in February 2001, Mr. Han has extensive experience in sales and marketing of herbal health products in Hong Kong and the United States, and he also worked as a marketing director of a herbal health products company in Hong Kong for four years. Mr. Han is the son of Ms. Yeh Shu Ping (an executive director and the Vice-chairman of the Company).

**Mr. Lee Hing Cheung, Eric**, aged 49, is the General Manager of the Company and is responsible for the Group's corporate development. Mr. Lee holds a Master of Science degree in Finance from the University of Strathclyde in the United Kingdom. Before joining the Group in July 2007, Mr. Lee has over 15 years of experience in investment banking and held senior positions in a number of reputable financial institutions in Hong Kong.

**Mr. Hui Pang To**, aged 49, is the Financial Controller and Company Secretary of the Company. Mr. Hui is responsible for the Group's corporate finance and accounting affairs. Mr. Hui is a fellow member of the Association of Chartered Certified Accountants in the United Kingdom and a member of the Hong Kong Institute of Certified Public Accountants. Mr. Hui graduated from the Lingnan University with a bachelor degree with honour in business administration in 1997. Before joining the Group in February 1999, Mr. Hui has over ten years of experience in auditing, accounting and finance and worked with an international accounting firm in Hong Kong.

# Corporate Governance Report

## CORPORATE GOVERNANCE PRACTICES

The Company recognizes the importance of corporate governance in maintaining its corporate transparency and accountability. The Board sets appropriate policies and implements corporate governance practices appropriate to the conduct and growth of the Group's business.

The Company has applied the principles as set out in the Corporate Governance Code (the "CG Code") contained in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

The Board considers that during the year ended 31 March 2018, the Company has applied the principles and complied with the code provisions set out in the CG Code, except for the code provision A.4.2. Key corporate governance principles and practices of the Company as well as the details of the foregoing deviation are summarized below.

### A. THE BOARD

#### A1. Responsibilities and Delegation

The Board is responsible for the leadership, control and management of the Company and oversees the Group's business, strategic decision and performances in the attainment of the objective of ensuring effective functioning and growth of the Group and enhancing value to investors. All the directors carry out their duties in good faith, take decisions objectively and act in the interests of the Company and its shareholders at all times.

The Board reserves for its decision on all major matters of the Company, including the approval and monitoring of all policy matters, overall strategies and budgets, internal control and risk management systems, material transactions (in particular those that may involve conflict of interests), financial information, appointment of directors and other significant financial and operational matters.

All directors have timely access to all relevant information as well as the advice and services of the Company Secretary and senior management, with a view to ensuring compliance with Board procedures and all applicable laws and regulations. Any director may request for independent professional advice in appropriate circumstances at the Company's expense, upon reasonable request made to the Board.

The Executive Committee and the senior management are delegated the authority and responsibilities by the Board for the day-to-day management and operation of the Group. The delegated functions and work tasks are periodically reviewed. Approval has to be obtained from the Board prior to any significant transactions entered into by the above-mentioned officers. The Board has the full support of the senior management to discharge its responsibilities.

# Corporate Governance Report

## A2. Board Composition

The composition of the Board as at 31 March 2018 is as follows:

*Executive directors:*

Dr. Chiu Ka Leung	<i>(Chairman of the Board, Chairman of the Nomination Committee, Member of both the Executive Committee and the Remuneration Committee)</i>
Ms. Yeh Shu Ping	<i>(Vice-chairman of the Board, Chief Executive Officer, Chairman of the Executive Committee and Member of the Remuneration Committee)</i>
Mr. Jiao Shaoliang	<i>(Member of the Executive Committee)</i>
Dr. He William (also known as Lu Pingguo)	<i>(Member of the Executive Committee)</i>

*Independent non-executive directors:*

Mr. Lam Siu Hung	<i>(Chairman of both the Audit Committee and the Remuneration Committee and Member of the Nomination Committee)</i>
Mr. Guo Guoqing	<i>(Member of the Audit Committee, the Remuneration Committee and the Nomination Committee)</i>
Mr. Kwok Hok Lun	<i>(Member of the Audit Committee, the Remuneration Committee and the Nomination Committee)</i>
Dr. Liu Zhonghua	<i>(Member of both the Remuneration Committee and the Nomination Committee)</i>

Throughout the year ended 31 March 2018, the Board has met the requirements of the Listing Rules 3.10 and 3.10A of having a minimum of three independent non-executive directors (representing at least one-third of the Board) with one of them possessing appropriate professional qualifications and accounting and related financial management expertise.

The members of the Board have skills and experience appropriate for the business requirements and objectives of the Group. Each executive director is responsible for different business and functional division of the Group in accordance with his/her expertise. The independent non-executive directors bring different business and financial expertise, experiences and independent judgement to the Board and they are invited to serve on the Board committees of the Company. Through participation in Board meetings, taking the lead in managing issues involving potential conflicts of interests, the independent non-executive directors had made contributions to the effective direction of the Company and provided adequate checks and balances to safeguard the interests of both the Group and the shareholders.

The biographical details of the directors of the Company as well as the relationships among Board members, if any, are set out in the section headed "Biographical Details of Directors and Senior Management" in this annual report.

The Company has received written annual confirmation from each independent non-executive director of his independence pursuant to the requirements of the Listing Rules. The Company considers all independent non-executive directors to be independent in light of the independence guidelines set out in the Listing Rules.

## A3. Chairman and Chief Executive Officer

The roles and duties of the Chairman and the Chief Executive Officer of the Company are held by separate persons and have been clearly defined in writing in order to ensure a balance of power and authority and preserve a balanced judgement of views. Currently, Dr. Chiu Ka Leung takes up the role of Chairman of the Board, and is responsible for the management of the Board and ensuring that all major and appropriate issues are discussed by the Board in a timely and constructive manner; whereas Ms. Yeh Shu Ping is the Chief Executive Officer of the Company, taking care of the day-to-day management of the Group's healthcare and pharmaceutical business and implementing the Group's policies, strategic plans and business goals formulated by the Board in relation to the healthcare and pharmaceutical business.

# Corporate Governance Report

## A4. Appointment and Re-election of Directors

All directors of the Company are appointed for a specific term, subject to renewal upon expiry of the existing term. Each executive director is engaged on a service agreement with the Company for a term of 2 years. The appointment may be terminated by either party by given not less than 3 months' written notice. Each of the independent non-executive directors of the Company is appointed for a term of 1 year.

According to the Company's Articles of Association (the "Articles"), one-third of the directors for the time being (if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation at each annual general meeting provided that every director shall be subject to retirement at an annual general meeting at least once every three years. In addition, any new director appointed to fill a casual vacancy or as an addition to the Board shall hold office only until the first general meeting after appointment. The retiring directors are eligible for re-election by the shareholders at the respective general meetings.

Code provision A.4.2 of the CG Code states that every director, including those appointed for a specific term, shall be subject to retirement by rotation at least once every three years. Due to the Audit Findings, the publication of annual results and dispatch of annual reports for the years ended 31 March 2017 and 2018, as well as the publication of interim results and dispatch of interim report for the six months ended 30 September 2017, are deferred until the date of this annual report. Accordingly, the Company failed to hold its annual general meeting within the times stipulated under the Listing Rules and the Articles, and that Mr. Jiao Shaoliang and Dr. He William did not retire by rotation at least once every 3 years in accordance with the said code provision A.4.2. At the forthcoming annual general meeting of the Company (the "AGM"), Ms. Yeh Shu Ping, Mr. Jiao Shaoliang, Dr. He William, Mr. Kwok Hok Lun and Dr. Liu Zhonghua shall retire, and being eligible, will offer themselves for re-election.

## A5. Training and Continuing Development for Directors

Each newly appointed director shall receive induction on the first occasion of his/her appointment, so as to ensure that he/she has appropriate understanding of the business and operations of the Group and that he/she is fully aware of his/her responsibilities and obligations under the Listing Rules and relevant regulatory requirements.

The existing directors are continually updated with legal and regulatory developments, and the business and market changes to facilitate the discharge of their responsibilities. Continuing briefings and professional development for directors are arranged whenever necessary. In addition, reading material on new or changes to salient laws and regulations applicable to the Group are provided to directors from time to time for their studying and reference.

During the year ended 31 March 2018, the directors complied with the code provision A.6.5 of the CG Code on participation in continuous professional training as follows:

- All directors (being Dr. Chiu Ka Leung, Ms. Yeh Shu Ping, Mr. Jiao Shaoliang, Dr. He William, Mr. Lam Siu Hung, Mr. Guo Guoqing, Mr. Kwok Hok Lun and Dr. Liu Zhonghua) received regular briefings and updates from the Company Secretary on the Group's business, operations and corporate governance matters; and read technical bulletins and other publications on subjects relevant to their responsibilities and obligations as directors under the Listing Rules and relevant regulatory requirements.
- Mr. Lam Siu Hung and Mr. Kwok Hok Lun attended seminars, which are relevant to their duties and responsibilities, organized by professional firms/institutions.
- The Company organised training sessions relating to directors' duties and responsibilities, and Dr. Chiu Ka Leung, Ms. Yeh Shu Ping, Mr. Jiao Shaoliang, Dr. He William, Mr. Lam Siu Hung, Mr. Guo Guoqing, Mr. Kwok Hok Lun and Dr. Liu Zhonghua, attended such training sessions.

# Corporate Governance Report

## A6. Directors' Attendance Records

The attendance records of each director at the Board and Board committee meetings and the general meetings of the Company held during the year ended 31 March 2018 are set out below:

Name of Director	Attendance/Number of Meetings				Extraordinary General Meeting
	Board	Audit Committee	Remuneration Committee	Nomination Committee	
<i>Executive directors:</i>					
Dr. Chiu Ka Leung	4/4	N/A	1/1	1/1	0/1
Ms. Yeh Shu Ping	4/4	N/A	1/1	N/A	0/1
Mr. Jiao Shaoliang	3/4	N/A	N/A	N/A	0/1
Dr. He William (also known as Lu Pingguo)	3/4	N/A	N/A	N/A	1/1
<i>Independent non-executive directors:</i>					
Mr. Lam Siu Hung	4/4	2/2	1/1	1/1	1/1
Mr. Guo Guoqing	3/4	2/2	1/1	1/1	0/1
Mr. Kwok Hok Lun	4/4	2/2	1/1	1/1	0/1
Dr. Liu Zhonghua	2/4	N/A	1/1	1/1	0/1

In addition, the Chairman of the Board held a meeting with the independent non-executive directors without the presence of executive directors, and a meeting with the executive directors without the presence of independent non-executive directors during the year under review.

## A7. Model Code for Securities Transactions

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") contained in Appendix 10 to the Listing Rules as its own code of conduct regarding directors' dealings in the Company's securities. Each director has been given a copy of the Model Code. Specific enquiry has been made of all the Company's directors and they have confirmed their compliance with the Model Code throughout the year ended 31 March 2018.

The Company has also established written guidelines on no less exacting terms than the Model Code (the "Employees Written Guidelines"), governing securities transactions by employees who are likely to possess inside information of the Company and/or its securities. No incident of non-compliance of the Employees Written Guidelines by the relevant employees was noted by the Company.

In case when the Company is aware of any restricted period for dealings in the Company's securities, the Company will notify its directors and relevant employees in advance.

## A8. Corporate Governance Functions

The Board is responsible for performing the corporate governance functions set out in the code provision D.3.1 of the CG Code.

During the year under review, the Board has performed such corporate governance functions as follows: (i) reviewed and developed the Company's corporate governance policies and practices, (ii) reviewed and monitored the training and continuous professional development of directors and senior management, (iii) reviewed and monitored the Company's policies and practices on compliance with legal and regulatory requirements, (iv) reviewed and monitored the compliance of the Model Code and the Employees Written Guidelines, and (v) reviewed the Company's compliance with the CG Code and disclosure in the Corporate Governance Report.

# Corporate Governance Report

## B. BOARD COMMITTEES

The Company has four Board committees, namely, the Executive Committee, the Remuneration Committee, the Nomination Committee and the Audit Committee, in the year ended 31 March 2018 for overseeing particular aspects of the Company's affairs. Subsequent to the year ended 31 March 2018, on 1 August 2018, an internal control committee was set up by the Company for enhancing the internal control procedures and corporate governance of the Group. All Board committees have been established with defined written terms of reference which are available on the Stock Exchange's website ([www.hkexnews.hk](http://www.hkexnews.hk)) and on the Company's website (except for the written terms of reference of the Executive Committee and the Internal Control Committee which are available to shareholders upon request). All the Board committees should report to the Board on their decisions or recommendations made.

All Board committees are provided with sufficient resources to discharge their duties and, upon reasonable request, are able to seek independent professional advice in appropriate circumstances, at the Company's expenses.

### B1. Executive Committee

The Executive Committee comprises all the executive directors of the Company with the Vice-chairman of the Board, Ms. Yeh Shu Ping, acting as the chairman of this Committee. Since its establishment in July 2005, the Executive Committee operates as a general management committee under the direct authority of the Board to increase the efficiency for the business decisions. It monitors the execution of the Company's strategic plans and operations of all business units of the Group, and discusses and makes decisions on matters relating to the management and day-to-day operations of the Company.

### B2. Remuneration Committee

The Remuneration Committee comprises a total of six members, being two executive directors, namely Dr. Chiu Ka Leung and Ms. Yeh Shu Ping, and four independent non-executive directors, namely Mr. Lam Siu Hung, Mr. Guo Guoqing, Mr. Kwok Hok Lun and Dr. Liu Zhonghua. The majority of the Remuneration Committee members are independent non-executive directors. The chairman of the Remuneration Committee is Mr. Lam Siu Hung.

The principal responsibilities of the Remuneration Committee include making recommendations to the Board on the Company's remuneration policy and structure and the remuneration packages of directors and members of senior management (i.e. the model described in the code provision B.1.2(c)(ii) of the CG Code is adopted). The Remuneration Committee is also responsible for establishing transparent procedures for developing such remuneration policy and structure to ensure that no director or any of his/her associates will participate in deciding his/her own remuneration, which remuneration will be determined by the Board with reference to the performance of the individual and the Company as well as market practice and conditions.

During the year ended 31 March 2018, the Remuneration Committee has held 1 meeting (the attendance records of each Committee member are set out in section A6 above) and performed the following major works:

- Review of the remuneration policy and structure of the Group; and
- Delegation of the power to the Company's executive directors to conduct an annual review on the remuneration packages of senior management and to make any appropriate adjustments.

# Corporate Governance Report

## B2. Remuneration Committee (Continued)

Pursuant to code provision B.1.5 of the CG Code, the annual remuneration of the members of the senior management by band for the year ended 31 March 2018 is set out below:

Remuneration band (HK\$)	Number of individual
HK\$1,500,001 to HK\$2,000,000	1
HK\$1,000,000 to HK\$1,500,000	2

Details of the remuneration of each director of the Company for the year ended 31 March 2018 are set out in note 7 to the consolidated financial statements contained in this annual report.

## B3. Nomination Committee

The Nomination Committee comprises a total of five members, being the Chairman of the Board, namely Dr. Chiu Ka Leung, and the four independent non-executive directors, namely Mr. Lam Siu Hung, Mr. Guo Guoqing, Mr. Kwok Hok Lun and Dr. Liu Zhonghua. Accordingly, a majority of the members are independent non-executive directors. The chairman of the Nomination Committee is Dr. Chiu Ka Leung.

The principal responsibilities of the Nomination Committee include reviewing the structure, size and composition (including the skills, knowledge and experience) of the Board on a regular basis and recommending any changes to the Board; identifying qualified and suitable individuals to become Board members and selecting and making recommendations to the Board on the selection of individuals nominated for directorships; assessing the independence of independent non-executive directors; and making recommendations to the Board on relevant matters relating to the appointment or re-appointment of directors and succession planning for directors in particular, the Chairman and the Chief Executive Officer of the Company.

In selecting candidates for directorship of the Company, the Nomination Committee may make reference to certain criteria such as the Company's needs, the diversity on the Board, the integrity, experience, skills and professional knowledge of the candidate and the amount of time and effort that the candidate will devote to discharge his/her duties and responsibilities. External recruitment professionals might be engaged to carry out selection process when necessary.

The Company also recognizes and embraces the benefit of having a diverse Board to enhance the quality of its performance and hence the purpose of the Board diversity. To comply with the code provision of A.5.6 of the CG Code, a Board diversity policy was adopted by the Company pursuant to which the Nomination Committee is responsible for monitoring the implementation of the Board diversity policy and assessing the Board composition under diversified perspectives (including but not limited to gender, age, cultural and educational background, professional qualifications, skills, knowledge and industry and regional experience). The Nomination Committee shall report its findings and make recommendation to the Board, if any. Such policy and objectives, if any, will be reviewed from time to time to ensure their appropriateness in determining the optimum composition of the Board.

The Nomination Committee considered an appropriate balance of diversity perspectives of the Board is maintained and has not set any measurable objective implementing the Board diversity policy.

# Corporate Governance Report

## B3. Nomination Committee (Continued)

During the year ended 31 March 2018, the Nomination Committee has held 1 meeting (the attendance records of each Committee member are set out in section A6 above) and performed the following major works:

- Review of the structure, size and composition of the Board to ensure that it has a balance of expertise, skills and experience appropriate to the requirements for the business of the Group; and
- Assessment of the independence of all the Company's independent non-executive directors.

## B4. Audit Committee

The Audit Committee comprises a total of three members, being three independent non-executive directors of the Company, namely Mr. Lam Siu Hung, Mr. Guo Guoqing and Mr. Kwok Hok Lun. The chairman of the Audit Committee is Mr. Lam Siu Hung who possesses the appropriate professional qualification, and accounting and financial management expertise as required under Rule 3.10(2) of the Listing Rules. None of the members of the Audit Committee is a former partner of the Company's existing external auditor.

The main duties of the Audit Committee are reviewing the financial information and reports of the Group and considering any significant or unusual items raised by the financial officers of the Group or external auditors before submission to the Board; reviewing the relationship with and the terms of appointment of the external auditors and making the relevant recommendation to the Board; and reviewing the Company's financial reporting system as well as risk management and internal control systems.

During the year ended 31 March 2018, the Audit Committee has held 2 meetings (the attendance records of each Committee member are set out in section A6 above) and performed the following major works:

- Review and discussion of the annual consolidated financial statements, results announcement and report for the year ended 31 March 2017, the related accounting principles and practices adopted by the Group and the relevant audit findings;
- Review and discussion of the interim financial statements, results announcements and reports for the six months ended 30 September 2016 and 30 September 2017 respectively, and the related accounting principles and practices adopted by the Group;
- Review and discussion of the continuing connected transactions of the Company for the years ended 31 March 2017 and 31 March 2018 respectively;
- Consideration and discussion of the major internal audit issues for the year ended 31 March 2017 and the six months ended 30 September 2017;

# Corporate Governance Report

## B4. Audit Committee (Continued)

- Assessment of the effectiveness of the Group's risk management and internal control systems based on the reports from external professional firms; and
- Consideration and recommendation of the change of external auditor of the Company from Ernst & Young to Moore Stephens CPA Limited and the re-appointment of Moore Stephens CPA Limited.

Ernst & Young and Moore Stephens CPA Limited attended the above meetings respectively to discuss with the Audit Committee members on issues arising from the audit and financial reporting matters. Besides, there is no disagreement between the Board and the Audit Committee regarding the appointment of Moore Stephens CPA Limited as external auditor of the Company.

## C. DIRECTORS' RESPONSIBILITIES FOR FINANCIAL REPORTING IN RESPECT OF THE FINANCIAL STATEMENTS

The directors of the Company have acknowledged their responsibilities for preparing the financial statements of the Group for the year ended 31 March 2018.

The Board is responsible for presenting a balanced, clear and understandable assessment of annual and interim reports, price sensitive announcements and other disclosures required under the Listing Rules and other regulatory requirements. The management has provided such explanation and information to the Board as necessary to enable the Board to make an informed assessment of the financial information and position of the Group put forward to the Board for approval.

There are no material uncertainties relating to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

## D. RISK MANAGEMENT AND INTERNAL CONTROL

The Board recognizes its responsibility for maintaining an adequate and sound enterprise risk management and internal control system and through the Audit Committee and, if necessary, an external firm of professional internal control consultants to provide internal control services, conducts reviews on the effectiveness of these systems at least annually, covering material controls, including financial, operational, compliance and strategic risk control functions. The Board understands that such systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss.

During the year under review, the Board, through the Audit Committee, conducted review of both design and implementation effectiveness of the risk management and internal control systems of the Group, covering all material controls, including financial, operational and compliance controls, with a view to ensuring that resources, staff qualifications and experience, training programmes and budget of the Group's accounting, internal audit and financial reporting functions are adequate.

During the performance of the audit work of the Company's consolidated financial statements for the year ended 31 March 2017, Ernst & Young identified certain inconsistencies in the financial information and supporting documents obtained. The publication of annual results and dispatch of annual report for the years ended 31 March 2017 and 2018, as well as the publication of interim results and dispatch of interim report for the six months ended 30 September 2017, are therefore deferred until the date of this annual report. Accordingly, the Company was not able to comply with the financial reporting provisions under Rules 13.46, 13.47, 13.48 and 13.49 of the Listing Rules.

# Corporate Governance Report

## D. RISK MANAGEMENT AND INTERNAL CONTROL (Continued)

In this respect, the Company appointed Baker Tilly Hong Kong Risk Assurance Limited (“Baker Tilly”), an external firm of professional internal control consultants, to assist in identifying and assessing the risks of the Group through a series of workshops and interviews, and independently perform internal control review and assess effectiveness of the Group’s risk management and internal control systems. Based on the review results of Baker Tilly, the Board is satisfied that the Group’s internal control system is sound and effective.

### Our Enterprise Risk Management Framework

The Group fine-tuned its enterprise risk management framework in 2018. While the Board has the overall responsibility to ensure that sound and effective internal controls are maintained, management is responsible for designing and implementing an internal control system to manage all kinds of risks faced by the Group.

Through the risk identification and assessment processes, risks are identified, assessed, prioritized and allocated treatments. Our risk management framework follows the COSO Enterprise Risk Management – Integrated Framework, which allows the Board and management to manage the risks of the Group effectively. The Board receives regular reports through the Audit Committee that oversees risk management and internal audit functions.

### Our Risk Control Mechanism

The Group adopts a “three-layer” corporate governance structure with operational management and controls performed by operations management, coupled with risk management monitoring carried out by the finance team and independent internal audit outsourced to and conducted by Baker Tilly. The Group maintains a risk register to keep track of all identified major risks of the Group. The risk register provides the Board, the Audit Committee, and management with a profile of its major risks and records management’s action taken to mitigate the relevant risks. Each risk is evaluated at least annually based on its likelihood of occurrence and potential impact upon the Group. The risk register is updated by management as the risk owners with addition of new risks and/or removal of existing risks, if applicable, at least annually, after the annual risk evaluation has been performed. This review process can ensure that the Group proactively manages the risks faced by it in the sense that all risk related parties have access to the risk register and are aware of and alert to those risks in their area of responsibility so that they can take follow-up action in an efficient manner.

Our risk management activities are performed by management on an ongoing process. The effectiveness of our risk management framework will be evaluated at least annually, and periodic management meeting is held to update the progress of risk monitoring efforts. Management is committed to ensuring that risk management forms part of the daily business operation processes in order to align risk management with corporate goals in an effective manner.

There is currently no internal audit function within the Group. The directors have reviewed the need for an internal audit function and are of the view that in light of the size, nature and complexity of the business of the Group, it would be more cost effective to appoint external independent professionals to perform internal audit function for the Group in order to meet its needs. Nevertheless, the directors will continue to review at least annually the need for an internal audit function.

The Company will continue to engage external independent professionals to review the Group’s system of internal controls and risk management annually and further enhance the Group’s internal control and risk management systems as appropriate.

# Corporate Governance Report

## E. COMPANY SECRETARY

The Company Secretary of the Company is Mr. Hui Pang To, who fulfils the qualification requirements laid down in the Listing Rules. Biographical details of Mr. Hui are set out in the section headed "Biographical Details of Directors and Senior Management" of this annual report. During the year ended 31 March 2018, Mr. Hui has taken not less than 15 hours of relevant professional training.

## F. EXTERNAL AUDITOR AND AUDITOR'S REMUNERATION

The statement of the external auditor of the Company about their reporting responsibilities on the Company's financial statements for the year ended 31 March 2018 is set out in the section headed "Independent Auditor's Report" in this annual report.

The fees paid/payable to the Company's auditor in respect of audit services and non-audit services for the year ended 31 March 2018 are analyzed below:

Type of services provided by the external auditor	Fees paid/payable (HK\$)
<i>Audit services by Moore Stephens CPA Limited:</i> audit fee for the year ended 31 March 2018	930,000
<i>Non-audit services by Moore Stephens CPA Limited:</i> agreed-upon procedures on interim financial information for the six months ended 30 September 2017	250,000
agreed-upon procedures on the revised interim result announcement for the six months ended 30 September 2016	80,000
<b>TOTAL:</b>	<b>1,260,000</b>

## G. COMMUNICATIONS WITH SHAREHOLDERS AND INVESTORS

The Company believes that effective communication with shareholders is essential for enhancing investor relations and investors' understanding of the Group's business performance and strategies. The Group also recognizes the importance of transparent and timely disclosure of corporate information, which enables shareholders and investors to make the best investment decision.

The Company maintains a website at [www.longruntea.com](http://www.longruntea.com) as a communication platform with shareholders and investors, where information and updates on the Company's business developments and operations and other information are available for public access. Shareholders and investors may send written enquiries or requests to the Company as follows:

Address: Unit 2201, 22/F, Bank of America Tower, 12 Harcourt Road, Central, Hong Kong/  
Room 3007A-B, Cable TV Tower, 9 Hoi Shing Road, Tsuen Wan, New Territories, Hong Kong

Fax number: (852) 3904 3464/(852) 3602 2868

Email: [ird@longruntea.com](mailto:ird@longruntea.com)

Inquiries are dealt with in an informative and timely manner.

# Corporate Governance Report

## H. SHAREHOLDERS' RIGHTS

To safeguard shareholders' interests and rights, separate resolutions are proposed at shareholders' meetings on each substantial issue, including the election of individual directors, for shareholders' consideration and voting. The Company's shareholders may convene an extraordinary general meeting or put forward proposals at shareholders' meetings as follows:

- (1) Shareholder(s) holding at the date of deposit of the requisition not less than one-tenth of the paid-up capital of the Company may request the Board to convene an extraordinary general meeting pursuant to Article 58 of the Articles by sending a written requisition to the Board or the Company Secretary at the Company's principal place of business in Hong Kong. The objects of the meeting must be stated in the written requisition.
- (2) If a shareholder wishes to propose a person other than a retiring director for election as a director of the Company at a general meeting, pursuant to Article 88 of the Articles, the shareholder (other than the person to be proposed) duly qualified to attend and vote at the general meeting shall send a written notice, duly signed by the shareholder, of his/her intention to propose such person for election and also a notice signed by the person to be proposed of his/her willingness to be elected. These notices should be lodged at the Company's principal place of business in Hong Kong, or the office of the Company's branch share registrar. The period for lodgement of such notices shall commence on the day after the dispatch of the notice of such general meeting and end on 7 days prior to the date of such general meeting.

For the avoidance of doubt, shareholder(s) must provide their full names, contact details and identification, in the originally signed written requisition, notice or statement (as the case may be), in order to give effect thereto. Information of shareholder(s) may be disclosed as required by law.

During the year under review, the Company has not made any significant changes to the Articles. An up-to-date version of the Articles is available on the websites of the Company and the Stock Exchange. Shareholders may refer to the Articles for further details of the rights of shareholders.

All resolutions put forward at shareholders' meetings of listed issuers shall be voted by poll pursuant to the Listing Rules. The poll voting results shall be posted on the websites of the Stock Exchange and the Company after each shareholders' meeting.

# Report of the Directors

The directors of the Company present this annual report and the audited consolidated financial statements for the year ended 31 March 2018.

## PRINCIPAL ACTIVITIES

The Company acts as an investment holding company. Details of the principal activities of its subsidiaries are set out in note 1 to the consolidated financial statements. There were no significant changes in the nature of the Group's principal activities during the year.

## BUSINESS REVIEW

A review of the business of the Group during the year, a discussion on the Group's future business development, an analysis of the Group's performance during the year using financial key performance indicators and a description of possible risks and uncertainties that the Group may be facing are set out in the Chairman's Statement and the Management Discussion and Analysis of this annual report. The financial risk management objectives and policies of the Group are set out in note 34 to the consolidated financial statements. In addition, discussions on the Group's relationships with its key stakeholders and compliance with relevant laws and regulations which have a significant impact on the Group are included in the Management Discussion and Analysis and the Corporate Governance Report of this annual report. The relevant discussions in the aforesaid sections form part of this report.

## RESULTS AND DIVIDENDS

The losses of the Group for the year ended 31 March 2018 and the state of affairs of the Group at that date are set out in the financial statements on pages 53 to 117.

The directors do not recommend the payment of a dividend for the year ended 31 March 2018 (2017: Nil).

## SUMMARY FINANCIAL INFORMATION

A summary of the published results and assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the audited consolidated financial statements, is set out on page 118. This summary does not form part of the audited consolidated financial statements of the Group for the year ended 31 March 2018.

## PROPERTY, PLANT AND EQUIPMENT

Details of movements in the property, plant and equipment of the Group during the year are set out in note 12 to the consolidated financial statements.

## SHARE CAPITAL AND CONVERTIBLE BONDS

Details of the Company's share capital and convertible bonds are set out in notes 24 and 22 to the consolidated financial statements respectively.

# Report of the Directors

## PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Articles or the laws of the Cayman Islands which would oblige the Company to offer new shares on a pro rata basis to its existing shareholders.

## PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY

Neither the Company, nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities during the year under review.

## RESERVES

Details of movements in the reserves of the Company and the Group during the year are set out in note 36 to the consolidated financial statements and in the Consolidated Statement of Changes in Equity on page 57 respectively.

## DISTRIBUTABLE RESERVES

At 31 March 2018, the Company's reserves available for distribution, calculated in accordance with the provisions of the Companies Law of the Cayman Islands, amounted to HKD63,733,000.

## CHARITABLE CONTRIBUTIONS

During the year, the Group made charitable contributions totalling HK\$8,291.

## ENVIRONMENTAL POLICIES

The Group encourages environmental protection and promotes such awareness to all its employees. The Group commits to the principle and practice of recycling and reducing. To help conserve the environment, the Group implements green office practices such as the use of recycled paper for printing and copying as well as double-sided printing and copying. The Group also encourages its employees to develop good habits, save resources and energy in order to build an environmentally-friendly and comfortable working environment. In addition, the Group reviews its environmental practices from time to time and considers implementing more eco-friendly measures, sustainability targets and practices in the operation of the Group's businesses to embrace the principles of reducing, recycling and reuse, and further minimize the impact on the natural environment.

Please refer to the Environmental, Social and Governance ("ESG") Report on pages 34 to 49 for further details of the Group's ESG-related risks, environmental policies and performance and other ESG information.

## MAJOR CUSTOMERS AND SUPPLIERS

During the year under review, purchases from the Group's five largest suppliers accounted for approximately 99% of the total purchases for the year and purchases from the largest supplier included therein amounted to approximately 38%.

During the year under review, sales to the Group's five largest customers accounted for approximately 20% of the total sales for the year and sales to the largest customer included therein amounted to approximately 6%.

Dr. Chiu Ka Leung, who is a director of the Company and has an attributable interest of 55.51% in the Company's share capital, had beneficial interests in the five largest suppliers which accounted for approximately 99% of the total purchases of the Group. Dr. Chiu Ka Leung also had beneficial interests in the largest customer which accounted for approximately 6% of the total sales of the Group.

Mr. Jiao Shaoliang, a director of the Company, had beneficial interests in the five largest suppliers which accounted for approximately 99% of the total purchases of the Group. Mr. Jiao Shaoliang also had beneficial interests in the largest customer which accounted for approximately 6% of the total sales of the Group.

Save as disclosed above, none of the directors of the Company or any of their close associates or any shareholders (which, to the best knowledge of the directors, own more than 5% of the Company's issued share capital) had any beneficial interest in the Group's five largest suppliers and customers.

# Report of the Directors

## DIRECTORS

The directors of the Company during the year and up to the date of this report were:

### Executive directors:

Dr. Chiu Ka Leung, *Chairman*  
Ms. Yeh Shu Ping, *Vice-chairman and Chief Executive Officer*  
Mr. Jiao Shaoliang  
Dr. He William (also known as Lu Pingguo)

### Independent non-executive directors:

Mr. Lam Siu Hung  
Mr. Guo Guoqing  
Mr. Kwok Hok Lun  
Dr. Liu Zhonghua

In accordance with the Articles and the agreement among the Directors, Ms. Yeh Shu Ping, Mr. Jiao Shaoliang, Dr. He William, Mr. Kwok Hok Lun and Dr. Liu Zhonghua, will retire as directors of the Company at the AGM. The above retiring directors, being eligible, will offer themselves for re-election at the AGM.

## DIRECTORS' SERVICE CONTRACTS

Each of the executive directors of the Company has entered into a service contract with the Company for a term of two years and is subject to termination by either party giving not less than three months' prior notice in writing. The executive directors are also subject to retirement by rotation in accordance with the Articles.

The independent non-executive directors of the Company have been appointed for a fixed term of one year and are subject to retirement by rotation in accordance with the Articles.

Apart from the foregoing, no director proposed for re-election at the AGM has a service contract with the Company which is not determinable by the Company or any of its subsidiaries within one year without payment of compensation, other than statutory compensation.

## DIRECTORS' REMUNERATION

The directors' fees are subject to shareholders' approval at general meetings. Other emoluments are determined by the Board with reference to directors' duties, responsibilities and performance and the results of the Group.

## DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Apart from the share option scheme operated by the Company as disclosed in the section headed "SHARE OPTIONS" and in note 25 to the consolidated financial statements, neither at the end of nor at any time during the year there subsisted any arrangement to which the Company, any of its subsidiaries or holding companies, was a party, and the objects of or one of the objects of such arrangement are/is to enable the Company's directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

# Report of the Directors

## DIRECTORS' INTERESTS IN TRANSACTIONS, ARRANGEMENTS OR CONTRACTS

Save as disclosed in the section headed "CONNECTED TRANSACTIONS" and in note 31 to the consolidated financial statements, neither director nor an entity connected with a director had a material interest, either directly or indirectly, in any transactions, arrangements or contracts of significance in relation to the business of the Group to which the Company, any of its subsidiaries or holding companies was a party subsisted at the end of the year or at any time during the year.

## CONTRACTS OF SIGNIFICANCE

Save as disclosed in the section headed "CONNECTED TRANSACTIONS" and in note 31 to the consolidated financial statements, no contracts of significance were entered into between the Company or any of its subsidiaries and a controlling shareholder or any of its subsidiaries during the year.

## MANAGEMENT CONTRACTS

No contracts concerning the management and administration of the whole or any substantial part of the business of the Company were entered into or existed during the year.

## PERMITTED INDEMNITY PROVISION

A permitted indemnity provision (as defined in the Hong Kong Companies Ordinance) for the benefit of the directors of the Company and its associated companies is currently in force and was in force throughout the year and at the date when the directors' report is approved.

## DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS IN SHARES AND UNDERLYING SHARES

As at 31 March 2018, the interests held by the directors and the chief executive of the Company and their respective associates in the shares, debentures and underlying shares of the Company and its associated corporations which were required, pursuant to Section 352 of the Securities and Futures Ordinance (the "SFO"), to be entered in the register referred to therein, or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange, were as follows:

### (A) Long position in ordinary shares of the Company

Name of director	Capacity	Number of ordinary shares	Percentage <sup>+</sup> of the Company's issued share capital
Dr. Chiu Ka Leung	Beneficial owner	805,804,500	55.51%
Ms. Yeh Shu Ping	Beneficial owner	35,545,500	2.45%
Mr. Jiao Shaoliang	Beneficial owner	1,100,000	0.08%
Dr. He William (also known as Lu Pingguo)	Beneficial owner	16,880,000	1.16%

# Report of the Directors

## DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS IN SHARES AND UNDERLYING SHARES (Continued)

### (B) Long position in underlying shares of the Company – physically settled unlisted equity derivatives

Name of director	Capacity	Number of underlying shares	Percentage <sup>+</sup> of underlying shares over the Company's issued share capital
Dr. Chiu Ka Leung	Beneficial owner	1,400,000	0.10%
Ms. Yeh Shu Ping	Beneficial owner	10,000,000	0.69%
Mr. Jiao Shaoliang	Beneficial owner	10,000,000	0.69%
Dr. He William (also known as Lu Pingguo)	Beneficial owner	10,000,000	0.69%
Mr. Lam Siu Hung	Beneficial owner	1,000,000	0.07%
Mr. Guo Guoqing	Beneficial owner	1,000,000	0.07%
Mr. Kwok Hok Lun	Beneficial owner	1,000,000	0.07%
Dr. Liu Zhonghua	Beneficial owner	1,000,000	0.07%

*Note:* Details of the above share options granted by the Company are set out in the section headed "SHARE OPTIONS" below.

<sup>+</sup> *The percentage represents the number of ordinary shares/underlying shares involved divided by the number of the Company's issued shares as at 31 March 2018.*

In addition to the above, as at 31 March 2018, Dr. Chiu Ka Leung holds one ordinary share in each of Long Far Herbal Medicine Manufacturing (Hong Kong) Limited and Long Far Health Products Limited (in both cases in trust for Long Far Pharmaceutical (BVI) Limited and both of which are indirect wholly-owned subsidiaries of the Company) in a non-beneficial capacity, solely for the purpose of complying with the then minimum company membership requirement.

Save as disclosed above and in the section headed "SHARE OPTIONS" below, as at 31 March 2018, none of the directors or chief executive of the Company or any of their associates had registered an interest or a short position in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

# Report of the Directors

## SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITION IN SHARES AND UNDERLYING SHARES

As at 31 March 2018, the following persons/corporations (other than directors or chief executive of the Company) who had interests or short position of 5% or more of the issued shares and underlying shares of the Company as recorded in the register of interests required to be kept by the Company pursuant to Section 336 of the SFO or as the Company is aware:

### (A) Long position in ordinary shares of the Company

Name	Capacity	Number of ordinary shares	Percentage <sup>+</sup> of the Company's issued share capital
Guo Jinxiu	Interest held by spouse (Note 1)	805,804,500	55.51%
Chen Fang	Beneficial owner	110,000,000	7.58%
徐永鋒	Beneficial owner	100,000,000	6.89%
Law Fei Shing	Interest of controlled corporations (Note 2)	764,215,000	52.65%
True Promise Investments Limited	Interest of controlled corporation (Note 2)	764,215,000	52.65%
Excel Precise International Limited	Person having a security interest in shares (Note 2)	764,215,000	52.65%

### (B) Long position in underlying shares of the Company – physically settled unlisted equity derivatives

Name	Capacity	Number of underlying shares	Percentage <sup>+</sup> of underlying shares over the Company's issued share capital
Guo Jinxiu	Interest held by spouse (Note 1)	1,400,000	0.10%

Notes:

- Ms. Guo Jinxiu, being the spouse of Dr. Chiu Ka Leung, was deemed to have such interest held by Dr. Chiu Ka Leung. Such interest of Dr. Chiu has been disclosed in the section headed "DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS IN SHARES AND UNDERLYING SHARES" above.
- Excel Precise International Limited was a company owned as to 25% by Mr. Law Fei Shing and 73.5% by True Promise Investments Limited. True Promise Investments Limited in turn was wholly-owned by Mr. Law Fei Shing. Accordingly, Mr. Law Fei Shing and True Promise Investments Limited were deemed to be interested in these shares which Excel Precise International Limited was deemed to have a security interest.

<sup>+</sup> The percentage represents the number of ordinary shares/underlying shares involved divided by the number of the Company's issued shares as at 31 March 2018.

Save as disclosed above, as at 31 March 2018, no person, other than the directors or chief executive of the Company whose interests are set out in the section headed "DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS IN SHARES AND UNDERLYING SHARES" above, had registered an interest or a short position in the shares, underlying shares or debentures of the Company as recorded in the register of interests required to be kept by the Company pursuant to Section 336 of the SFO.

# Report of the Directors

## SHARE OPTIONS

As set out in note 25 to the consolidated financial statements, the Company currently operates a share option scheme adopted on 17 August 2012 (the "Scheme") (which is made pursuant to Chapter 17 of the Listing Rules) for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. Eligible participants of the Scheme include the directors of the Company (including independent non-executive directors), other employees of the Group, suppliers of goods or services to the Group, customers of the Group and holders of securities of the Group. The Scheme became effective on 17 August 2012 and, unless otherwise cancelled or amended, would remain in force for 10 years from that date. Details of the movements of the Company's share options granted under the Scheme during the year ended 31 March 2018 are as follows:

Name or category of option holder	Number of share options				Outstanding as at 31 March 2018	Date of grant of share options	Exercise period of share options	Exercise price per share (Note)
	Outstanding as at 1 April 2017	Granted during the year	Exercised during the year	Lapsed/cancelled during the year				
<b>Directors</b>								
<i>Executive directors:</i>								
Dr. Chiu Ka Leung	1,400,000	-	-	-	1,400,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
Ms. Yeh Shu Ping	10,000,000	-	-	-	10,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
Mr. Jiao Shaoliang	10,000,000	-	-	-	10,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
Dr. He William (also known as Lu Pingguo)	10,000,000	-	-	-	10,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
<i>Independent non-executive directors:</i>								
Mr. Lam Siu Hung	1,000,000	-	-	-	1,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
Mr. Guo Guoqing	1,000,000	-	-	-	1,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
Mr. Kwok Hok Lun	1,000,000	-	-	-	1,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
Dr. Liu Zhonghua	1,000,000	-	-	-	1,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
<b>Subtotal for directors:</b>	<b>35,400,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>35,400,000</b>			
<b>Employees of the Group</b>								
In aggregate	16,000,000	-	-	-	16,000,000	25 November 2016	25 November 2016 to 24 November 2021	HK\$0.30
<b>Subtotal for employees:</b>	<b>16,000,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>16,000,000</b>			
<b>TOTAL:</b>	<b>51,400,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>51,400,000</b>			

# Report of the Directors

## SHARE OPTIONS(Continued)

*Note:*

The number and/or exercise price of the share options may be subject to adjustment in the case of rights or bonus issues, or other changes in the Company's share capital.

As at the date of this annual report, the total number of securities of the Company available for issue under the Scheme was 142,952,000 shares, representing approximately 9.85% of the issued share capital of the Company as at the date of this annual report.

## ISSUE OF CONVERTIBLE BONDS

On 9 December 2016, the Company entered into the placing agreement (the "CB Placing Agreement") with Supreme China Securities Limited, pursuant to which the Company had agreed to appoint Supreme China Securities Limited as the placing agent for the purpose of procuring not less than six independent professional, institutional or other investors as the placees to subscribe in cash for the convertible bonds in a maximum aggregate principal amount of up to HK\$64,800,000 issued by the Company on the terms and subject to the conditions set out in the CB Placing Agreement. The Board considers that the CB Placing Agreement represented an opportunity to potentially enlarge and diversify the shareholder base of the Company and to raise further working capital for the Group.

The completion of the CB Placing Agreement took place on 27 January 2017. Convertible bonds in the principal amount of HK\$64,800,000 (the "Convertible Bonds") have been issued by the Company to 7 placees. The Convertible Bonds can be converted into 240,000,000 ordinary shares of the Company at any time on or before 5 business days immediately prior to 28 January 2019 at a fixed conversion price of HK\$0.27 subject to certain anti-dilutive adjustments at the discretion of the holders that are independent third parties. The net proceeds from issuing the Convertible Bonds of HK\$62,967,000 were intended to be used for the Company's possible future investments in the healthcare sector and for the settlement of the Group's general administrative expenses. As at the end of the financial year and the date when the directors' report is approved, no notice has been received from the holders requesting conversion. If all of the Convertible Bonds outstanding as at the end of the year were converted into ordinary shares of the Company at the conversion price of HK\$0.27, 240,000,000 ordinary shares of the Company will be issued.

Please also refer to note 22 to the consolidated financial statements and announcements of the Company dated 11 December 2016, 19 January 2017, 27 January 2017 and 6 February 2017 (the "Announcements") for further details of the Convertible Bonds.

# Report of the Directors

## UPDATE ON USE OF PROCEEDS IN RELATION TO FUND RAISING ACTIVITIES

The Company would like to provide the update in respect of the use of the net proceeds in relation to the past fund raising activities during the financial year 2018 as at 31 March 2018:

Reference is made to the Announcements in relation to placing of and issue of convertible bonds. Unless otherwise stated, capitalised terms used herein shall bear the same meanings as defined in the Announcements.

<b>Intended use of proceeds (as disclosed in the announcement of the Company dated 19 January 2017)</b>	<b>Actual use of proceeds during the financial year 2018</b>	<b>Intended use of proceeds after the financial year 2018</b>
---	--	---

An amount of net proceeds of HK\$62,967,000 was raised from issue of HK\$64.8 million 5.5% interest Convertible Bonds in January 2017 and the net proceeds were intended to use as follows:

- |  |  |  |
|--|--|--|
| (a) an amount of approximately HK\$27.8 million to be used for the possible future investments in the healthcare sector, in particular, in the manufacturing and/or trading of healthcare products such as pharmaceutical products, dietary supplements and health food; and   | an amount of HK\$27.8 million has not been utilised. | Such intended use of proceeds will remain unchanged. |
| (b) an amount of approximately HK\$35 million to be used for the settlement of the Group's general administrative expenses (including staff and related costs, legal and professional fees, finance costs, rental expenses and other administrative expenses) for the next 18 months from the date of the announcement of the Company dated 19 January 2017. | an amount of HK\$35 million has not been utilised.   | Such intended use of proceeds will remain unchanged. |

# Report of the Directors

## EQUITY-LINKED AGREEMENTS

Other than the Scheme and the CB Placing Agreement as disclosed above and in notes 22 and 25 to the consolidated financial statements, no equity-linked agreements that will or may result in the Company issuing shares or that require the Company to enter into any agreements that will or may result in the Company issuing shares were entered into by the Company during the year or subsisted at the end of the year.

## SUFFICIENCY OF PUBLIC FLOAT

Based on the information that is publicly available to the Company and within the knowledge of the directors of the Company as at the date of this report, there is sufficient public float of not less than 25% of the Company's issued shares as required under the Listing Rules.

## CONNECTED TRANSACTIONS

During the year, the Group had the following continuing connected transactions, certain details of which are disclosed in compliance with the requirements of Chapter 14A of the Listing Rules.

### (1) Purchase of Tea Products

On 12 May 2009, 雲南龍潤茶科技有限公司 (Yunnan Longrun Tea Technology Company Limited\*) ("YNLR", an indirect wholly-owned subsidiary of the Company) entered into an exclusive purchase agreement (the "Purchase Agreement") with 雲南龍潤茶業集團有限公司 (Yunnan Longrun Tea Group Company Limited\*) ("LRTG"), being a connected person of the Company within the meaning of the Listing Rules since Dr. Chiu Ka Leung and Mr. Jiao Shaoliang were directly interested in 97% and 3%, respectively, of the issued share capital of LRTG, for a term of 10 years. Pursuant to the Purchase Agreement, YNLR is granted an exclusive right to purchase the tea products and tea-related food products manufactured by LRTG (the "Tea Products") and to use the trademarks (including both registered and unregistered trademarks) owned by LRTG and its subsidiaries (such transaction be hereinafter referred to as the "Transaction 1"). As such, all the Tea Products are sold to YNLR. YNLR, through developing its own distribution network of self-owned stores and franchised stores, is distributing the Tea Products to the market. With the Purchase Agreement, a long-term contract in place, YNLR is able to secure the exclusive supply of high quality of Tea Products at favourable purchase terms.

The purchase price of the Tea Products payable by YNLR to LRTG is the lower of: (i) the production costs of the Tea Products or the book value of the inventory of LRTG plus a premium which does not exceed 10% of such production costs or book value; or (ii) the selling price of tea products of similar quality as that of the Tea Products which can be obtained by YNLR from other independent manufacturers. The premium of 10% was determined on normal commercial terms with reference to historical costs incurred by LRTG to carry out its business.

The annual caps of the amount of purchase of the Tea Products pursuant to the Purchase Agreement payable by YNLR to LRTG arising from the Transaction 1 approved by the independent shareholders of the Company at the extraordinary general meeting of the Company held on 16 June 2016 for each of the three financial years ended/ending 31 March 2017, 31 March 2018 and 31 March 2019 was HK\$148,000,000, HK\$166,000,000 and HK\$186,000,000 respectively. For the year ended 31 March 2018, the amount of fees paid to LRTG under the Transaction 1 amounted to HK\$43,695,000, which was within the above annual cap amount for the financial year ended 31 March 2018 of HK\$166,000,000. Further details of the Transaction 1 are included in note 31(a) to the consolidated financial statements.

\* For identification purposes only

# Report of the Directors

## CONNECTED TRANSACTIONS (Continued)

### (2) Sale of Tea Products

YNLR has been supplying the tea products and tea-related product (the “Products”) to 理想科技集團有限公司 (Ideality Technology Group Company Limited\*) (“Ideality Group”) since 2014. During the period from 1 April 2017 to 14 January 2018, the Products supplied to Ideality Group by YNLR amounted to approximately RMB1,564,300 (equivalent to approximately HK\$1,907,700 based on the exchange rate of HK\$1.00 = RMB0.82). In light of the anticipated increasing demand for the Products in Chinese New Year, it was expected that the transaction amount for the Products between YNLR and Ideality Group would exceed HK\$3,000,000 (being the de minimis threshold set out in Rule 14A.76 of the Listing Rules) but below HK\$10,000,000 in aggregate for the financial year ended 31 March 2018.

On 15 January 2018, YNLR entered into a sales agreement (the “Sales Agreement”) with Ideality Group, being a connected person of the Company within the meaning of the Listing Rules since Dr. Chiu Ka Leung and Mr. Jiao Shaoliang were directly interested in 85.5% and 14.5%, respectively, of the issued share capital of Ideality Group, for a term from 15 January 2018 to 31 March 2018. Pursuant to the Sales Agreement, YNLR would sell the Products to Ideality Group (such transaction be hereinafter referred to as the “Transaction 2”, and together with “Transaction 1”, collectively referred to as the “Transactions”). As such, the Group can have access to the direct selling distribution channel and generate extra revenue.

The prices of the Products are negotiated between YNLR and Ideality Group on an arm’s length basis, on normal commercial terms, with reference and comparable to the prevailing market prices of the same or similar type of products, and no less favourable than those terms offered to independent third parties.

Pursuant to the Sales Agreement, the maximum amount of sales of the Products by YNLR to Ideality Group arising from the Transaction 2 within its term commencing on 15 January 2018 and ending on 31 March 2018 was RMB6,300,000 (equivalent to approximately HK\$7,683,000 based on the exchange rate of HK\$1.00 = RMB0.82). For the year ended 31 March 2018, the amount of sales of the Products received from Ideality Group under the Transaction 2 amounted to HK\$4,530,000, which was within the above maximum sales amount of HK\$7,683,000. Further details of the Transaction 2 are included in note 31(a) to the consolidated financial statements.

The independent non-executive directors of the Company have reviewed the Transactions for the year ended 31 March 2018 and confirmed that the Transactions had been entered into by the Group: (a) in its ordinary and usual course of business of the Group; (b) on normal commercial terms or better; and (c) in accordance with the Purchase Agreement/the Sales Agreement governing them on terms that were fair and reasonable and in the interests of the shareholders of the Company as a whole.

Moore Stephens CPA Limited, the Company’s auditor, were engaged to report on the Group’s continuing connected transactions in accordance with Hong Kong Standard on Assurance Engagements 3000 *Assurance Engagements Other Than Audits or Reviews of Historical Financial Information* and with reference to Practice Note 740 *Auditor’s Letter on Continuing Connected Transactions under the Hong Kong Listing Rules* issued by the Hong Kong Institute of Certified Public Accountants. Moore Stephens CPA Limited have issued their unqualified letter containing their findings and conclusions in respect of the continuing connected transactions disclosed above by the Group in accordance with the Listing Rules. A copy of the auditor’s letter has been provided by the Company to the Stock Exchange.

# Report of the Directors

## DIRECTORS' INTERESTS IN A COMPETING BUSINESS

During the year and up to the date of this report, the following directors have interested in a business which is likely to compete, either directly or indirectly, with the businesses of the Group, details of which are set out below:

- (1) Dr. Chiu Ka Leung has a controlling interest in 雲南盤龍雲海藥業有限公司 (Yunnan Panlong Yunhai Pharmaceutical Company Limited\*) ("YPYP") which is principally engaged in the development, manufacture and distribution of Chinese pharmaceutical products in Mainland China; and
- (2) Dr. Chiu Ka Leung and Mr. Jiao Shaoliang have a controlling interest in 雲南龍發製藥股份有限公司 (Yunnan Longfar Pharmaceutical Company Limited\*) ("YNLF"), which is engaged in the development, manufacture and distribution of Chinese pharmaceutical products in Mainland China.

The Group manufactures and distributes pharmaceutical and healthcare products under the Group's brand name of "龍發製藥" (Long Far) in Hong Kong, Southeast Asia and other Asian regions outside Mainland China. Given the difference in market presence, the directors considered that the operations of YPYP and YNLF will not affect the Group's pharmaceutical business.

Save as disclosed above, all directors have confirmed that neither themselves nor their respective associates (as defined in the Listing Rules) had held any position or had interest in any businesses or companies that were or might be materially competing with the business of the Group, or gave rise to any concern regarding conflict of interests during the year under review.

## CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Wednesday, 19 December 2018 to Monday, 24 December 2018 (both days inclusive), during which period no share transfer will be effected. In order to qualify for attending and voting at the forthcoming annual general meeting of the Company to be held on 24 December 2018, unregistered holders of shares of the Company should ensure that all completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, no later than 4:30 p.m. on Tuesday, 18 December 2018.

## AUDITORS

Upon the passing of the special resolution and ordinary resolution proposed at the Company's extraordinary general meeting held on 4 October 2017, Ernst & Young was removed and Moore Stephens CPA Limited was appointed as auditors of the Company for the year ended 31 March 2017. The consolidated financial statements of the Group for the year ended 31 March 2018 were audited by Moore Stephens CPA Limited.

Moore Stephens CPA Limited will retire and a resolution will be proposed at the AGM for their re-appointment as auditors of the Company.

ON BEHALF OF THE BOARD

**Chiu Ka Leung**  
*Chairman*

Hong Kong  
10 October 2018

\* For identification purposes only

# Environmental, Social and Governance Report

## 1. APPROACH

Longrun Tea Group Company Limited (the “Company”) and its subsidiaries (collectively the “Group” or “We”) were involved in the trading and distribution of pharmaceutical products, tea products and the food products. As a listed company, it is our corporate duty to promote transparency in relation to our business operations; as such, we would like to present our Environmental, Social and Governance (“ESG”) Report which highlights the operational strategies that have been carried out by us during this financial year to achieve sustainability in all aspects.

We consider corporate sustainability as the key to the long-term healthy development of our Group. As a responsible and caring corporation, we value work ethics as much as we cherish the opportunities to engage in sustainable development. For instance, we recognize our obligations to contribute to environmental sustainability, support our employees and strengthen community relations. When considering sustainability, we take into account a number of short-and long-term factors, including, but not limited to, business-related challenges, accountability to stakeholders, global trend of best practices of environmental protection, relevant laws and regulations, and risk management. We believe that the key to success in the overall approach of ESG is to ensure management makes informed decisions through thorough and ongoing review and monitoring of the ESG issues with the participation of all stakeholders. Hence, we have included KPIs in our ESG Report this year in order to give our stakeholders and the public a more comprehensive and profound understanding of the effectiveness of the implemented operational strategies in pursuing environmental sustainability.

Nowadays, sustainability is not merely a concept, but an ultimate goal for all mankind. We are embracing opportunities and managing risks derived from the economy, environment and society in order to meet overarching targets. We believe that upholding the value of sustainability in our business dealings will better position in allocating resources and benefiting our stakeholders and the community.

## 2. ABOUT THE ESG REPORT

We are delighted to present the ESG Report (the “Report”) in 2017/18. This Report herein focuses on providing an overview of the environmental and social aspects of the Group, and outlines how we seek to continually improve our operational strategy in regard to our environment and society in order to cope with the global standards of sustainability.

During the process of the preparation of this Report, the Group has conducted thorough review and evaluation of the existing Group’s policies and practices. Unless otherwise stated, this Report focuses on the Group’s tea business in the PRC due to its materiality towards environmental and social impact. We focuses on an indirect wholly-owned and major revenue generating subsidiary of the Company, 雲南龍潤茶科技有限公司 (Yunnan Longrun Tea Technology Company Limited) (“YNLR”), in the People’s Republic of China (the “PRC”). The Group will continue to strengthen our information collection process in order to disclose a more comprehensive set of information with regard to our sustainable operations in both the PRC and Hong Kong in our ESG Report in 2018/19 and beyond.

# Environmental, Social and Governance Report

## 2.1 Report Scope and Boundary

The Report is prepared in accordance with the ESG Reporting Guide (“Guide”) as set out in Appendix 27 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“HKEX”) (the “Listing Rules”).

In order to comply with the disclosure obligations of “comply or explain” provisions, this Report has outlined the overall Group’s performance in environmental protection, human resources, operating practice and community involvement for the financial year, from 1 April 2017 to 31 March 2018 (“Reporting Period”). HKEX’s Guide is provided for cross-referencing purpose and is shown from pages 45 to 49 of the Report.

We acknowledge the importance of proper disclosure of business activities, believing it as the key to building trust with investors and shareholders. For instance, this Report will highlight the following aspects:

- Emissions, Use of Resources and Generation of Waste;
- Employment and Labour Practices;
- Operating Practices; and
- Community Investment.

This Report was approved by the board of directors (the “Board”) on 10/10/2018. For details of corporate governance, please refer to the “Corporate Governance Report” on pages 11 to 21 of the Annual Report.

## 2.2 Information and Feedback

For details in relation to our financial performance during the financial year, please visit our website: <http://www.longruntea.com> or Annual Report.

Your feedback and comments are our greatest motivation to improve our ESG performance. Please send us an email to [info@longfar.com.hk](mailto:info@longfar.com.hk), if you have any queries as for the content of this Report or the Group’s sustainability policies.

# Environmental, Social and Governance Report

## 2.3 Our Stakeholders

We believe that our stakeholders play an important role in sustaining the success of our business, and we seek for opportunities to understand and engage our stakeholders. The probable points of concern of the stakeholders and the means of our communication and responses are listed below.

Stakeholders	Probable Points of Concern	Communication and Responses
HKEX	Compliance with listing rules, and timely and accurate announcements.	Meetings, training, workshops, programs, website updates, and announcements.
Government	Compliance with laws and regulations, preventing tax evasion, and social welfare.	Interaction and visits, government inspections, tax returns and other information.
Investors	Corporate governance, business strategies and performance, and investment returns.	Organizing briefing sessions and seminars, interviews, shareholders' meetings, issue of financial reports or operation reports for investors, media and analysts.
Media & Public	Corporate governance, environmental protection, and human rights.	Issue of newsletters on the Company's website.
Customers	Service quality, service delivery schedule, reasonable prices, service value, and personal data protection.	After-sales services.
Employees	Rights and benefits of employees, compensation, training and development, work hours, and working environment.	Conducting union activities, training, interviews with employees, internal memos, and employee suggestion boxes.
Community	Community environment, employment opportunities, community development, and social welfare.	Developing community activities, employee voluntary activities, and community welfare subsidies and donations.

# Environmental, Social and Governance Report

## 3. PROTECTING OUR ENVIRONMENT

As a responsible enterprise, the Group is committed to protecting the surrounding environment and reducing its impact on the environment caused by its business operations.

The Group is well aware that the foundation of social prosperity is a healthy environment. As such, we have been persistent in conducting business in an environmentally sustainable manner through efficient use of resources and implementing green initiatives.

During the Reporting Period, we strictly complied with all applicable environmental laws and regulations in the PRC, including but not limited to the "Environmental Protection Law of the PRC" (中華人民共和國環境保護法), and the "Law of the PRC on Prevention and Control of Water Pollution" (中華人民共和國水污染防治法).

### 3.1 Emissions

The Group mainly engages in the trading of tea products. The business operations do not involve any production processes. Despite the fact that there are no direct air and greenhouse gas emissions from our business operations, they are generated through two types of our activities, including the use of motor vehicles and the consumption of electricity.

During the Reporting Period, YNLR produced 250.47 kg of Nitrogen Oxides, 0.46 kg of Sulphur Oxides, 24.00 kg of Particulate Matter and 426,338.47 kg of Carbon Dioxide. Details of the emissions are summarized as below.

Emission Indicators	Source	Unit	Emission Type	Data
<b>KPI A1.1</b>				(in g)
Emission Data from Vehicles				
	Kilometres travelled	283,012 km	Nitrogen Oxides	250,465.62
			Particulate Matter	23,999.42
	Units of fuel consumed			
	Petrol	31,501 L	Sulphur Oxides	463.07
<b>KPI A1.2</b>				
Total Greenhouse Gas ("GHG") Emissions				(in kg)
Scope 1: Direct Emissions or Removals from Sources				
Scope 1b – GHG Emissions from Mobile Combustion Sources	Units of fuel consumed			
	Petrol	31,501 L	Carbon Dioxide	85,267.55
Scope 2 – Energy Indirect Emissions				
	Unit of Electricity Consumed	393,120 kWh	Carbon Dioxide	341,070.91
Total Amount of Carbon Dioxide Produced during the Reporting Period:				426,338.47

There were no cases of non-compliance with laws and regulations relating to air pollution and greenhouse gas emissions during the Reporting Period.

# Environmental, Social and Governance Report

## 3.2 Green Operations

It is our belief that environmental commitment is more than merely operational compliance with the relevant local laws and regulations. Therefore, apart from fulfilling legal obligations in respect of air and greenhouse gas emissions that have a significant impact on us, we have worked further to establish a sound mechanism that aims for lower emissions and stronger environmental awareness of employees.

We are mindful of our obligations to reduce air and greenhouse gas emissions from its operations. A number of measures have been implemented to achieve the reduction of emissions, such as optimizing its route plans for transportation and product delivery; encouraging the use of public transportation; and replacing unnecessary overseas business travel with video conferencing, in respect of which business travel by air is only considered when it is unavoidable in order to minimize carbon emissions.

## 3.3 Hazardous Waste & Non-Hazardous Waste

No hazardous waste was produced from the ordinary course of business. The major non-hazardous waste produced was waste paper, all of which had been properly recycled.

Waste paper generated during the Reporting Period is detailed below.

Non-hazardous waste indicators	Source	Unit
<b>KPI1.4</b>		(in tonnes)
Total non-hazardous waste produced		
	Waste Paper	0.65820
Non-hazardous waste produced per tonne of unit produced		(in tonnes/ unit produced)
	Waste Paper	0.00001

There were no cases of non-compliance with laws and regulations relating to generation of non-hazardous waste during the Reporting Period.

## 3.4 Paperless Office

To promote a paperless office and reduce carbon emissions, we encourage the use of electronic systems to substitute paper-based office administration systems (OA System), and electronic means for information dissemination are used wherever possible. We make use of waste paper collection boxes, purchase printing paper with recycled content, and regularly evaluate paper consumption. Furthermore, employees are recommended to set the computers and printers to duplex and economical modes as default, and use smaller fonts and line spacing for inevitable printing to lower paper consumption. A notice is also placed at the side of the printer to remind employees to use double-sided photocopying and reuse used paper.

# Environmental, Social and Governance Report

## 3.5 Energy Conservation

Electricity is mainly consumed for the daily operations of offices and retail shops to support the lighting and air-conditioning systems. Electricity consumption during the Reporting Period are detailed below.

Energy Consumption	Source	Unit
<b>KPI2.1</b>		
Total Consumption		
	Electricity	393,120.00 kWh
Consumption per capita		
	Electricity	1,604.57 kWh per capita

As part of the initiatives to reduce energy consumption of lighting system, we require lighting to be switched off when it is not in use, maximizes the use of natural light, and divides the office area into different lighting zones controlled by independent switches. YNLR has also installed motion sensors in areas that are not frequently used, and reduced unnecessary lighting fixtures in order to lower energy consumption. Moreover, we clean the light fixtures regularly and adopts energy-efficient lighting to increase the energy efficiency of the lighting system. We also allow employees to dress in casual attire in office every Friday and in hot weather so as to reduce energy consumption.

## 3.6 Water Usage

As the Group does not involve tea processing, water consumption is relatively low. We do not have any issue in sourcing water, and water is mainly consumed by staff in the office and retail shops. The total consumption of water during the Reporting Period is detailed below.

Water Consumption	Source	Unit
<b>KPI2.2</b>		
Total Consumption		
	Water	2,379.00 cubic meters
Consumption per capita		
	Water	9.71 cubic meters per capita

To minimize water consumption, water-efficient equipment is used and water pressure is set to an optimal level. Moreover, water leakage test and water meter reading check are conducted regularly to detect and address any issue related to water leakage, dripping taps or abnormal water usage in a timely manner. In addition, water-saving notices are also displayed in the toilets to remind employees to turn off the water taps after use.

Domestic sewage is filtered in septic tanks and undergoes wastewater treatment conducted by the wastewater treatment plant before the wastewater is discharged into municipal sewage pipeline network. As such, our environmental footprint can be further reduced.

## 3.7 Packaging Materials

There were no packaging materials produced during the course of our operations in the PRC.

# Environmental, Social and Governance Report

## 4. CARING OUR EMPLOYEES

We strive to achieve long-term growth and sustainable development by placing emphasis on the interests and rights of our employees and creating a comfortable and safe working environment.

To protect the rights of our employees, the Group complies with all relevant laws and regulations that have a significant impact on us, including but not limited to, the "Labour Law of the PRC", "Labour Contract Law of the PRC", and "Law of the PRC on Work Safety".

During the Reporting Period, there was no incident of non-compliance in relation to the relevant labour laws and regulations, and the Group had not been subject to any claim, lawsuit, penalty or disciplinary action.

### 4.1 Employment and Welfare

Employees are our greatest assets, and have been the major driving force of our continual success. We strive to provide a working environment free from discrimination and harassment, and offer equal opportunities along with attractive and competitive remuneration.

We have established our internal policies in accordance with the relevant labour laws and regulations related to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.

To ensure that key company policies are clearly communicated to our employees, YNLR has established a "Staff Handbook", which details the rights of our employees, such as working hours, leave entitlement and other benefits and welfare. Each employee is provided with a copy of the "Staff Handbook" when they join the Group.

During the recruitment process, job applicants who meet the job requirements are given equal interview opportunities. All applicants are assessed based on their ability, irrespective of their nationality, race, religion, disability, sexual orientation, political opinion, gender, age or family status. Through proactive enforcement of our anti-discrimination policy, we aspire to create a harmonious workplace free of bullying and belittling.


To prevent employment of child labour, newly recruited employees are required to provide a copy of identification documents for age verification. Signing employment contracts with our employees, which clearly state the job positions of the employees, is also an essential part of our employment process to prevent forced labour. If we discover any cases of child and/or forced labour, we will immediately terminate the employment concerned and investigate into the incident. Disciplinary action may be taken against any staff members who are responsible for the causes of the incident. Pursuant to the relevant laws and regulations, exit interviews are to be arranged and outstanding wages are to be settled in a timely manner upon resignation of any employees.

To ensure there is sufficient rest time for our employees, we manage the work schedules such that our staff in PRC work no more than 8 working hours per day and 40 hours per week. The aforementioned working hour arrangement is established in accordance with the requirements stipulated in the "Labour Law of the PRC". Employees who have completed their probation are entitled to all statutory holidays, leave and welfare as stipulated in the national and local laws and regulations, including but not limited to paid maternity leave, paternity leave, marriage leave and compassionate leave.

# Environmental, Social and Governance Report

As part of our effort to retain talents, remuneration package for employees are reviewed periodically on the basis of industry practice and performance of the Group and individual employees.

As of 31 March 2018, the Group had a total of 244 employees. The breakdowns of our workforce by gender, age and employment level are as follows.



During the Reporting Period, 208 employees left the Group with turnover rates as follows.

## Employee Turnover Rate

### By Gender

Male	37%
Female	63%

### By Age

<25	49%
25 – 29	42%
30 – 39	7%
40 – 49	1%
> 50	1%

# Environmental, Social and Governance Report

## 4.2 Health and Safety

To maintain a healthy and safe workplace for our employees, the Group strictly abides by the local laws and regulations related to occupational health and safety that have a significant impact on us. Safety procedures for high risk projects and necessary protective equipment are available to protect employees from injuries and health risks. With a vision of creating a workplace free of accidents, we conduct equipment maintenance from time to time. Clear guideline for handling emergencies is also formulated in case of occurrence of accidents. Throughout the Reporting Period, there were no work-related fatalities and lost days due to work injury.

## 4.3 Training and Development

A talented workforce is of paramount importance to the continuous success of the Group and therefore, the Group invests considerably in employees' career development. Apart from on-the-job-training, in-house training is provided to our employees. We also encourage our employees to enrol in external courses in disciplines related to their work by subsidizing them with the relevant fees incurred. Appraisals are conducted regularly to review the performance of our employees. Employees with outstanding performance are given promotion opportunities.

During the Reporting Period, YNLR provided staff training in a total of 793 hours. The statistics related to staff training and development is detailed as follows.

	<b>For the Year ended 31st March 2018</b>
<b>Average no. of hours of training per employee</b>	
<b>By Gender</b>	
Male	21.57
Female	24.88
<b>By employment category</b>	
Entry level	23.70
Middle level	12.95
Management level	2.00
<b>Percentage of employees trained</b>	
<b>For the Year ended 31st March 2018</b>	
<b>By gender</b>	
Male	53.9%
Female	46.1%
<b>By employee category</b>	
Entry level	88.3%
Middle level	10.2%
Management level	1.5%

# Environmental, Social and Governance Report

## 5. OPERATING PRACTICES

Our business success represents our responsible and meticulous manner in every aspect of our business operations, from supply chain, product responsibility to anti-corruption, underpinned by our unwavering conviction to deliver quality products to our customers.

During the Reporting Period, the Group was not aware of any non-compliance with the relevant laws and regulations related to health and safety, advertising, labelling and privacy matters relating to the products and services provided and methods of redress.

### 5.1 Supply Chain Management

During the Reporting Period, the Group made purchases from 5 major suppliers in China. We work closely with our suppliers to ensure quality and to minimize the environmental impact of our products.

When selecting suppliers, the Group ensures that they are certified and able to meet the national and industrial requirements. Moreover, the selection of suppliers also involves careful consideration of product quality, product safety, location of suppliers and delivery time to minimize the social risks of the supply chain.

### 5.2 Quality Assurance

During the Reporting Period, we complied with all relevant laws and regulations in relation to quality assurance that have a significant impact on us, including but not limited to, "Food Safety Law of People's Republic of China" (中華人民共和國食品安全法) and "Measures for Management of Food Licensing" (食品經營許可管理辦法) and "Product Quality Law of the PRC" (中華人民共和國產品質量法). Our goal is to provide quality products to our customers, not only do we abide by relevant local laws and regulations in regard to product quality and safety, we also endeavor to provide safe and healthy products through the establishment of stringent quality control and examination procedures.

All products are stored under dry and well-ventilated conditions with regular checks conducted to ensure that the products are kept in a good condition. In case of any severe quality or safety issues that arise after sales, we will promptly recall the defective products or take actions to lessen the impact on the society. In the event of quality defects, customers retain the rights of returning the purchases to the Group within 7 calendar days.

During the Reporting Period, YNLR had a total of 44,915.0 units of products were sold, out of which 27.6 units were subjected to recalls due to safety and health reasons, accounting for less than 0.1% of total products sold.

### 5.3 Management of Advertising

To promote our products to our potential customers, we conduct marketing activities and promotional events through online platforms, social media, and exhibitions, etc. In strict compliance with the laws and regulations related to advertisement and labelling, such as the "Advertisement Law of the PRC" (中華人民共和國廣告法), we ensure that all information and descriptions of marketing and advertising, including public sales to be legal, accurate and truthful.

# Environmental, Social and Governance Report

## 5.4 Protection of Customer Data and Privacy

In order to protect customer data and privacy, the Group closely observes the relevant laws and regulations, as well as implementing policies to manage confidential information and improve cyber security. Employees who have access to confidential information are required to sign non-disclosure agreements that forbid disclosure of information to other parties without express consent of the Group. Moreover, training related to privacy and cyber security are also provided to our employees to enhance their awareness of privacy.

## 5.5 Complaint Handling

Our well established procedures for handling customers' complaints reflect how we value customers' feedback, which helps us improve product quality and services and thereby, drives long-term growth of the Group. Customers may lodge complaints by telephone, in writing and/or via online platform. YNLR ensures that all complaints are treated in a prompt and consistent manner. Our employees, meanwhile, maintain good communication with our customers to understand their needs. Measures are taken to solve their issues, and improve our performance. During the Reporting Period, we did not receive any written complaints related to product and service quality.

## 5.6 Protection of Intellectual Property

During the Reporting Period, we strictly complied with laws and regulations in regard to product responsibility in Hong Kong and the PRC that have a significant impact on us, such as "Trademark Law of the PRC"(中華人民共和國商標法).

We strive to protect our intellectual property rights by prolonged use and registration of domain names and trademarks. Trademarks are registered in the PRC and other relevant jurisdictions. In addition, we constantly monitor and renew our intellectual properties upon their expiration.

## 5.7 Anti-corruption

The Group strictly adheres to the anti-corruption laws and regulations, such as the "Criminal Law of the PRC"(中華人民共和國刑法), and upholds its business integrity throughout the operations. Our procurement process requires suppliers to follow the relevant laws and regulations and prohibits bribery for business advantages or any improper purpose. Moreover, employees are required to follow the code of conduct, which is formulated with the purpose of preventing conflicts of interest, bribery and other unlawful behaviour, as well as misconduct. Whistle-blowing procedures are established for employees to report suspected corrupt practices or misconducts to senior management. Disciplinary actions, such as dismissal, may be taken against employees who breach the Group's code of conduct.

During the Reporting Period, no corruption and money laundering cases were noted or reported.

## 6. CONTRIBUTING TO OUR COMMUNITY

The Group supports various philanthropic initiatives. We strive to create a positive impact on the communities where we operate. Going forward, we are committed to continuing our social sustainability practices, with an ultimate aim to maximize the welfare of our community.

The Group believes that education is the foundation of community development. By supporting educational initiatives, we aspire to promote the prosperity of the local community. On 3 January 2018, we made a donation of RMB7,000 to Yun Tian Hua Middle School in Yunnan Province, the PRC.

# Environmental, Social and Governance Report

## HKEX'S GUIDE TO THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

### Part A: Environmental

ESG Aspects	Related Section	Remarks
<b>A1. Emissions</b>		
Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Protecting our Environment, Green Operations, Paperless Office, Energy Conservation and Water Usage	
KPI A1.1 The types of emissions and respective emission data.	Emissions	
KPI A1.2 Greenhouse gas emission in total (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Emissions	
KPI A1.3 Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	N/A	No hazardous waste is produced from our daily operations.
KPI A1.4 Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Hazardous Waste & Non-Hazardous Waste	
KPI A1.5 Description of measures to mitigate emissions and results achieved.	Green Operations and Energy Conservation	
KPI A1.6 Description of how hazardous and non-hazardous wastes are handled, reduction initiatives and results achieved	Hazardous Waste & Non-Hazardous Waste and Paperless Office	

# Environmental, Social and Governance Report

## HKEX'S GUIDE TO THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT (Continued)

### Part A: Environmental (Continued)

ESG Aspects	Related Section	Remarks
<b>A2. Use of Resources</b>		
Policies on the efficient use of resources, including energy, water and other raw materials.	Paperless Office, Energy Conservation, Water Usage and Packaging Materials	
KPI A2.1 Direct and/or indirect energy consumption by type. (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Energy Conservation	
KPI A2.2 Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Water Usage	
KPI A2.3 Description of energy use efficiency initiatives and results achieved.	Energy Conservation	
KPI A2.4 Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency initiatives and results achieved.	Water Usage	
KPI A2.5 Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Packaging Materials	
<b>A3. The Environmental and Natural Resources</b>		
Policies on minimizing the issuer's significant impact on the environment and natural resources.	Green Operations, Paperless Office, Energy Conservation and Water Usage	
KPI A3.1 Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Green Operations, Paperless Office, Energy Conservation and Water Usage	

# Environmental, Social and Governance Report

## HKEX'S GUIDE TO THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT (Continued)

### Part B: Social

ESG Aspects	Related Section	Remarks
<b>B1. Employment</b>		
Information on the policies and compliance with laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Caring our Employees, Employment and Welfare	
KPI B1.1 Total workforce by gender, employment type, age group and geographical region.	Employment and Welfare	
KPI B1.2 Employment turnover rate by gender, age group and geographical region.	Employment and Welfare	
<b>B2. Health and Safety</b>		
Information on the policies and compliance with laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Health and Safety	
KPI B2.1 Number and rate of work-related fatalities.	Health and Safety	
KPI B2.2 Lost days due to work injury.	Health and Safety	
KPI B2.3 Description of occupational health and safety measures adopted, how they are implemented and monitored.	Health and Safety	
<b>B3. Development and training</b>		
Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Training and Development	
KPI B3.1 The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	Training and Development	
KPI B3.2 The average training hours completed per employee by gender and employee category.	Training and Development	

# Environmental, Social and Governance Report

## HKEX'S GUIDE TO THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT (Continued)

### Part B: Social (Continued)

ESG Aspects	Related Section	Remarks
<b>B4. Labour standards</b>		
Information on the policies and compliance with laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Employment and Welfare	
KPI B4.1 Description of measures to review employment practices to avoid child and forced labour.	Employment and Welfare	
KPI B4.2 Description of steps taken to eliminate such practices when discovered.	Employment and Welfare	
<b>B5. Supply chain management</b>		
Policies on managing environmental and social risks of the supply chain.	Supply Chain Management	
KPI B5.1 Number of suppliers by geographical region.	Supply Chain Management	
KPI B5.2 Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, how they are implemented and monitored.	Supply Chain Management	
<b>B6. Product responsibility</b>		
Information on the policies and compliance with laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labeling and privacy matters relating to products and services provided and method of redress.	Operating Practices, Quality Assurance, Management on Advertising, Protection of Customer Data and Privacy	
KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Quality Assurance	
KPI B6.2 Number of products and service related complaints received and how they are dealt with.	Compliant Handling	

# Environmental, Social and Governance Report

## HKEX'S GUIDE TO THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT (Continued)

### Part B: Social (Continued)

ESG Aspects	Related Section	Remarks
KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.	Protection of Intellectual Property	
KPI B6.4 Description of quality assurance process and recall procedures.	Quality Assurance	
KPI B6.5 Description of consumer data protection and privacy policies, how they are implemented and monitored.	Protection of Customer Data and Privacy	
<b>B7. Anti-corruption</b>		
Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Anti-corruption	
KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Anti-corruption	
KPI B7.2 Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored.	Anti-corruption	
<b>B8. Community investment</b>		
Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure that its activities take into consideration the communities' interests.	Contributing to our Community	
KPI B8.1 Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	Contributing to our Community	
KPI B8.2 Resources contributed (e.g. money or time) to the focus area.	Contributing to our Community	

# Independent Auditor's Report

**MOORE STEPHENS**

Moore Stephens CPA Limited  
801-806 Silvercord, Tower 1,  
30 Canton Road, Tsimshatsui,  
Kowloon, Hong Kong

T +852 2375 3180  
F +852 2375 3828

[www.moorestephens.com.hk](http://www.moorestephens.com.hk)

大華馬施雲  
會計師事務所有限公司

Independent Auditor's Report to the Members of  
Longrun Tea Group Company Limited  
(Incorporated in Cayman Islands with limited liability)

## DISCLAIMER OF OPINION

We were engaged to audit the consolidated financial statements of Longrun Tea Group Company Limited (the "Company") and its subsidiaries (the "Group") set out on pages 53 to 117, which comprise the consolidated statement of financial position as at 31 March 2018, and the consolidated statement of profit or loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended and notes to the consolidated financial statements, including a summary of significant accounting policies.

We do not express an opinion on the consolidated financial statements of the Group. Because of the significance of the matters described in the Basis for Disclaimer of Opinion section of our report we are unable to form an opinion as to whether the consolidated financial statements give a true and fair view of the financial position of the Group as at 31 March 2018 and of the Group's financial performance and cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). In all other respects, in our opinion the consolidated financial statements have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

## BASIS FOR DISCLAIMER OF OPINION

There was a loan receivable and corresponding interest receivable with the carrying amount of HK\$155,138,000 (equivalent to RMB137,570,000) and HK\$5,917,000 (equivalent to RMB5,247,000) which were only recorded in the Group's consolidated statement of financial position in May 2017 (the "Loan"). Prior to the Loan being recognised as a loan receivable in the Group's consolidated statement of financial position, the said balance of RMB137,570,000 was included in the bank balances account in the accounting books of the Group. During the year ended 31 March 2018, the Loan and the corresponding interest receivables of approximately HK\$169,836,000 (equivalent to RMB143,394,000) were received by the Group and presented in the consolidated statement of cash flows under investing activities. Interest income from the Loan of approximately HK\$683,000 (equivalent to RMB577,000) was recognised in the consolidated statement of profit or loss during the year ended 31 March 2018.

# Independent Auditor's Report (Continued)

## BASIS FOR DISCLAIMER OF OPINION (Continued)

The directors of the Company explained that the omission of recording the Loan (approved by two directors of a subsidiary who are also directors of the Company) which led to significant discrepancies of the bank balances as recorded in the accounting books and the bank statements and confirmations until May 2017 was caused by certain accounting staff of a subsidiary and internal control weakness associated with the granting, execution and recording of the Loan. These staffs were suspended from their duties in May 2017 and dismissed in September 2017. The Loan was asserted by the directors of the above mentioned subsidiary as being advanced to a borrower who is independent of the Group, any of the directors of the Company or any of the substantial shareholders of the Company.

Given the circumstances described above and the significance of the Loan to the consolidated financial statements, we were unable to perform audit procedures to satisfy ourselves regarding the nature and reasons for the discrepancies described above, particularly the omission of recording the Loan and interest in the Group's accounting books and consolidated financial statements until the discovery of discrepancies in the bank balances by the predecessor auditors of the Company in May 2017. The scope of our audit work was limited and we were unable to obtain sufficient appropriate audit evidence to satisfy ourselves about these matters, as well as the underlying commercial reasons of entering into the Loan. Any adjustments found to be necessary may have significant effects on the figures as at and for the year ended 31 March 2017 presented as comparative figures in these consolidated financial statements and hence on the comparability of the current year's figures and the comparative figures.

The matters which were the subject matters of the scope limitation referred to above no longer have possible effects on the figures presented in the consolidated statement of financial position of the Group as at 31 March 2018. However, the closing balances as at 31 March 2017 of the assets and liabilities of the Group, including that of the Loan, are brought forward as the opening balances as at 1 April 2017 and hence entered into the determination of the financial performance and cash flows of the Group for the current financial year ended 31 March 2018. Hence, any adjustments found to be necessary to the closing balances of the assets and liabilities as at 31 March 2017 in respect of the Loan may have significant effects on the Group's results and cash flows for the year ended 31 March 2018 and related disclosures in the notes to the consolidated financial statements of the Group for the year ended 31 March 2018. Accordingly, we were also unable to determine whether adjustments might have been necessary in respect of the performance and cash flows of the Group for the year ended 31 March 2018 reported in the consolidated statement of profit or loss and other comprehensive income and consolidated statement of cash flows.

## RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors of the Company determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors of the Company either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The Audit Committee assists the directors of the Company in discharging their responsibilities for overseeing the Group's financial reporting process.

## Independent Auditor's Report (Continued)

### AUDITOR'S RESPONSIBILITY FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our responsibility is to conduct an audit of the consolidated financial statements in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA and to issue an auditor's report. However, because of the matters described in the Basis for Disclaimer of Opinion section of our report, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these consolidated financial statements.

We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants (the "Code") and we have fulfilled our other ethical responsibilities in accordance with the Code.

**Moore Stephens CPA Limited**  
*Certified Public Accountants*

**Hung, Wan Fong Joanne**  
Practising Certificate Number: P05419

Hong Kong, 10 October 2018

# Consolidated Statement of Profit or Loss

For the year ended 31 March 2018

	Notes	2018 HK\$'000	2017 HK\$'000
REVENUE	4	81,670	123,690
Cost of sales		(48,158)	(72,712)
Gross profit		33,512	50,978
Other income	4	3,601	6,416
Interest income from loan receivable	17	683	5,863
Equity-settled share option expense	25	–	(6,311)
Gain on disposal of items of property, plant and equipment, net		58	168
Selling and distribution expenses		(30,429)	(39,448)
Administrative expenses		(30,946)	(30,996)
Other expenses		(41)	(17,185)
Finance costs	6	(10,325)	(1,652)
LOSS BEFORE TAX	5	(33,887)	(32,167)
Income tax expense	9	(15)	(264)
LOSS FOR THE YEAR		(33,902)	(32,431)
Loss attributable to owners of the Company		(33,902)	(32,431)
LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY			
Basic	11	HK(2.34) cents	HK(2.24) cents
Diluted		HK(2.34) cents	HK(2.24) cents

# Consolidated Statement of Comprehensive Income

For the year ended 31 March 2018

	2018 HK\$'000	2017 HK\$'000
LOSS FOR THE YEAR	<b>(33,902)</b>	(32,431)
OTHER COMPREHENSIVE INCOME		
<i>Items that may be reclassified subsequently to profit or loss:</i>		
Exchange differences arising on translation of foreign operations	<b>13,836</b>	(8,905)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF INCOME TAX	<b>13,836</b>	(8,905)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	<b>(20,066)</b>	(41,336)
Total comprehensive loss attributable to owners of the Company	<b>(20,066)</b>	(41,336)

# Consolidated Statement of Financial Position

At 31 March 2018

	Notes	2018 HK\$'000	2017 HK\$'000
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	12	2,401	2,566
Available-for-sale financial assets	13	7,500	–
<b>Total non-current assets</b>		<b>9,901</b>	2,566
<b>CURRENT ASSETS</b>			
Inventories	14	2,119	3,974
Trade receivables	15	27,010	25,392
Prepayments, deposits and other receivables	16	8,967	6,661
Loan receivable	17	–	161,055
Time deposits with original maturities of more than three months	18	96,313	30,593
Cash and cash equivalents	18	153,336	111,439
<b>Total current assets</b>		<b>287,745</b>	339,114
<b>CURRENT LIABILITIES</b>			
Trade payables	19	1,661	22,383
Other payables, accruals and receipts in advance	20	48,435	56,047
Finance leases payables	21	267	409
Convertible bonds	22	58,767	–
Income tax payables		2	–
Due to related companies	31(b)(i)	168	1,409
Due to directors of the Company	31(b)(ii)	3,750	3,507
<b>Total current liabilities</b>		<b>113,050</b>	83,755
<b>NET CURRENT ASSETS</b>		<b>174,695</b>	255,359
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>184,596</b>	257,925

# Consolidated Statement of Financial Position (Continued)

At 31 March 2018

	<i>Notes</i>	<b>2018</b> <b>HK\$'000</b>	2017 HK\$'000
<b>NON-CURRENT LIABILITIES</b>			
Convertible bonds	22	–	52,032
Finance leases payables	21	<b>200</b>	467
Deferred income		<b>186</b>	1,150
<b>Total non-current liabilities</b>		<b>386</b>	53,649
<b>Net assets</b>		<b>184,210</b>	204,276
<b>EQUITY</b>			
<b>Equity attributable to owners of the Company</b>			
Share capital	24	<b>72,576</b>	72,576
Reserves	26	<b>111,634</b>	131,700
<b>Total equity</b>		<b>184,210</b>	204,276

The consolidated financial statements on pages 53 to 117 were approved and authorised for issue by the board of directors on 10 October 2018 and are signed on its behalf by:

**Yeh Shu Ping**  
*Director*

**Jiao Shaoliang**  
*Director*

# Consolidated Statement of Changes in Equity

For the year ended 31 March 2018

	Notes	Issued Share Capital HK\$'000	Share premium HK\$'000	Contributed surplus HK\$'000 (note 26a)	Employee share-based compensation reserve HK\$'000 (note 26b)	Convertible bonds equity reserve HK\$'000 (note 22)	Exchange fluctuation reserve HK\$'000 (note 26c)	Accumulated losses HK\$'000	Total equity HK\$'000
<b>At 1 April 2016</b>		72,476	252,319	300	-	-	8,704	(107,647)	226,152
Loss for the year		-	-	-	-	-	-	(32,431)	(32,431)
Other comprehensive loss for the year:									
Exchange differences on translation of foreign operations		-	-	-	-	-	(8,905)	-	(8,905)
Total comprehensive loss for the year		-	-	-	-	-	(8,905)	(32,431)	(41,336)
Recognition of equity component of Convertible Bonds	22	-	-	-	-	12,914	-	-	12,914
Transaction costs attributable to issuance of Convertible Bonds allocated to equity component	22	-	-	-	-	(365)	-	-	(365)
Recognition of equity – settled share based payments	25	-	-	-	6,311	-	-	-	6,311
Exercise of share options	25	100	682	-	(182)	-	-	-	600
<b>At 31 March 2017 and 1 April 2017</b>		72,576	253,001*	300*	6,129*	12,549*	(201)*	(140,078)*	204,276
Loss for the year		-	-	-	-	-	-	(33,902)	(33,902)
Other comprehensive income for the year:									
Exchange differences on translation of foreign operations		-	-	-	-	-	13,836	-	13,836
Total comprehensive loss for the year		-	-	-	-	-	13,836	(33,902)	(20,066)
<b>At 31 March 2018</b>		72,576	253,001*	300*	6,129*	12,549*	13,635*	(173,980)*	184,210

\* These reserve accounts comprise the consolidated reserves of HK\$111,634,000 (2017: HK\$131,700,000) in the consolidated statement of financial position.

# Consolidated Statement of Cash Flows

For the year ended 31 March 2018

	Notes	2018 HK\$'000	2017 HK\$'000
<b>OPERATING ACTIVITIES</b>			
Loss before tax		<b>(33,887)</b>	(32,167)
Adjustments for:			
Finance costs	6	<b>10,325</b>	1,652
Interest income from bank deposits	4	<b>(1,299)</b>	(2,324)
Interest income from loan receivable		<b>(683)</b>	(5,863)
Equity-settled share option expense	25	–	6,311
Depreciation	5	<b>1,045</b>	1,414
Write off of items of property, plant and equipment	5	–	383
Gain on disposal of items of property, plant and equipment, net		<b>(58)</b>	(168)
Impairment losses of trade receivables	5	<b>2,819</b>	18,142
Impairment losses of other receivables	5	–	118
Reversal of impairment losses of trade receivables	5	<b>(2,730)</b>	(1,459)
Reversal of impairment losses of other receivables	5	<b>(68)</b>	–
Provision for slow-moving and obsolete inventories	5	<b>10</b>	101
Operating cash flows before movements in working capital		<b>(24,526)</b>	(13,860)
Decrease/(increase) in inventories		<b>2,080</b>	(458)
Decrease in trade receivables		<b>826</b>	4,770
(Increase)/decrease in prepayments, deposits and other receivables		<b>(1,526)</b>	1,090
(Decrease)/increase in amounts due to related companies		<b>(1,320)</b>	823
(Decrease) in trade payables		<b>(21,876)</b>	(4,430)
(Decrease)/increase in other payables, accruals and receipts in advance		<b>(11,663)</b>	2,935
(Decrease) in deferred income		<b>(1,031)</b>	(3,158)
Cash used in operations		<b>(59,036)</b>	(12,288)
PRC enterprise income tax paid		<b>(13)</b>	(76)
Net cash flows used in operating activities		<b>(59,049)</b>	(12,364)
<b>INVESTING ACTIVITIES</b>			
Interest received	4	<b>1,299</b>	2,324
Repayment of advance/(advance) of a loan receivable		<b>169,836</b>	(158,791)
Purchases of items of property, plant and equipment		<b>(722)</b>	(430)
Proceeds from disposal of items of property, plant and equipment		<b>66</b>	168
Purchases of available-for-sale financial assets		<b>(7,500)</b>	–
Cash inflows from disposal of subsidiaries		–	49,825
(Placement)/withdrawal of short term time deposits with original maturities of more than three months		<b>(65,720)</b>	119,185
Net cash flows generated from investing activities		<b>97,259</b>	12,281

## Consolidated Statement of Cash Flows (Continued)

For the year ended 31 March 2018

	<i>Notes</i>	<b>2018</b> <b>HK\$'000</b>	2017 HK\$'000
<b>FINANCING ACTIVITIES</b>			
Transaction costs on issuance of convertible bonds		–	(1,833)
Proceeds from issuance of convertible bonds		–	64,800
Payment of interests on convertible bonds	27	<b>(3,564)</b>	–
Proceeds from issue of shares upon exercise of share options		–	600
Repayments of finance leases payables	27	<b>(409)</b>	(438)
Advances/(Repayments of advances) from directors of the Company	27	<b>243</b>	(4,438)
Payment of interests on finance leases	27	<b>(26)</b>	(38)
Net cash flows (used in)/generated from financing activities		<b>(3,756)</b>	58,653
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>			
Cash and cash equivalents at beginning of year		<b>111,439</b>	53,053
Effect of foreign exchange rate changes, net		<b>7,443</b>	(184)
<b>CASH AND CASH EQUIVALENTS AT END OF YEAR</b>		<b>153,336</b>	111,439
<b>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</b>			
Cash and bank balances	18	<b>153,336</b>	21,218
Time deposits with original maturities of less than three months	18	–	90,221
Cash and cash equivalents as stated in the consolidated statement of financial position and the consolidated statement of cash flows		<b>153,336</b>	111,439

# Notes to the Consolidated Financial Statements

For the year ended 31 March 2018

## 1. CORPORATE AND GROUP INFORMATION

The Company is a public limited liability company incorporated in the Cayman Islands and its shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The principal place of business of the Company is disclosed in the corporate information section to the annual report. During the year, the Company and its subsidiaries (collectively referred as the "Group") were involved in the trading, distribution of pharmaceutical products, tea products and other food products.

### Information about principal subsidiaries of the Company

Particulars of the Company's principal subsidiaries are as follows as at 31 March 2018 and 2017:

Name of Subsidiary	Place of incorporation/ registration and operations	Issued ordinary share/ registered capital	Proportion of ownership interest held by the Company	Principal activities
Long Far Pharmaceutical (BVI) Limited ("Long Far Pharmaceutical")	British Virgin Islands	US\$200	100	Investment holding
Long Far Herbal Medicine Manufacturing (Hong Kong) Limited ("LFHK")	Hong Kong	Ordinary shares HK\$10 and non-voting deferred shares* HK\$100,000	100*	Trading of pharmaceutical products
Winlead Investment Limited	British Virgin Islands	US\$1	100	Investment holding
Long Far Health Products Limited	Hong Kong	HK\$2	100	Trading of health products
Long Far Investment (Hong Kong) Limited	Hong Kong	HK\$1	100	Dormant
Long Far Pharmaceutical (Macau) Limited	Macau	MOP25,000	100	Dormant
Longrun Tea Wealth Creation Company Limited ("Longrun Tea Wealth")	British Virgin Islands	US\$1	100	Investment holding
Longrun Tea Trading Company Limited	Hong Kong	HK\$1	100	Trading of tea products
雲南龍潤茶科技有限公司 (Yunnan Longrun Tea Technology Company Limited)**® ("YNLR")	The People's Republic of China (the "PRC" or "Mainland China")/Mainland China	HK\$47,000,000	100	Trading of tea products

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 1. CORPORATE AND GROUP INFORMATION (Continued)

### Information about principal subsidiaries of the Company (Continued)

Name of Subsidiary	Place of incorporation/ registration and operations	Issued ordinary share/ registered capital	Proportion of ownership interest held by the Company	Principal activities
Longrun Tea Online Shopping Company Limited	Hong Kong	HK\$1	100	Trading of tea products
雲南有你茶餐有限公司 (Yunnan Yuntea Company Limited)**®	The PRC/ Mainland China	Renminbi ("RMB") 8,000,000	100	Operation of tea shop
元陽縣龍潤茶業有限公司 (Yuanyang Xian Longrun Tea Trading Company Limited)**®#	The PRC/ Mainland China	RMB6,000,000	100	Dormant

\* In accordance with the articles of association of LFHK, shareholders of non-voting deferred shares are not entitled to any dividend, any participation in the profits or assets of LFHK (unless the distribution of the net assets for the first HK\$100,000 billion is made to the ordinary shareholders), and are also not entitled to vote at any general meeting.

The percentage of equity interest attributable to the Company represents to the ordinary shares.

\*\* Registered as a wholly-foreign-owned enterprise under the PRC law.

® Official names of these entities are in Chinese. The English translation of the names is for identification purpose only.

# Incorporated in March 2017.

Except for Long Far Pharmaceutical and Longrun Tea Wealth, all the above subsidiaries are indirectly held by the Company.

The above table lists the subsidiaries of the Group which, in the opinion of the directors of the Company, principally affected the results or assets of the Group. To give details of other subsidiaries would, in the opinion of the directors of the Company, result in particulars of excessive length.

None of the subsidiaries had issued any debt securities at the end of the year.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES

These consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”), which collective term includes all applicable Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (“HKASs”) and Interpretations issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”), accounting principles generally accepted in Hong Kong and the applicable disclosure requirements of the Hong Kong Companies Ordinance. These consolidated financial statements also comply with the applicable disclosure requirements under the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”).

These consolidated financial statements have been prepared on the historical cost convention except for available-for-sale financial assets that are measured at fair values on initial recognition and at subsequent period end dates. These consolidated financial statements are presented in Hong Kong dollars (“HK\$”), which is also the Company’s functional currency, and all values are rounded to the nearest thousand except when otherwise indicated.

The principal accounting policies and methods of computation used by the Group in the preparation of the consolidated financial statements for the year ended 31 March 2018 are consistent with those adopted in the consolidated financial statements for the year ended 31 March 2017, except for the adoption of the new and revised HKFRSs as explained in (a) below. The Group has not applied any new standard that is not yet mandatorily effective for the current accounting period (*note 37*).

Impacts of the adoption of new and revised HKFRSs are discussed below.

### (a) Adoption of new and revised HKFRSs

The Group has applied the following amendments to HKFRSs issued by the HKICPA for the first time in the current year:

HKAS 7 Amendments	Disclosure Initiative
HKAS 12 Amendments	Recognition of Deferred Tax Assets for Unrealised Losses
HKFRS 12 Amendments included in the Annual improvements to HKFRSs 2014-2016 Cycle	Disclosure of Interests in Other Entities: Clarification of the Scope of HKFRS 12

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (a) Adoption of new and revised HKFRSs (Continued)

Except for the HKAS 7 Amendments as described below, the application of above amendments to HKFRSs in the current year has had no material impact on the Group's financial performance and positions for the current and prior years and/or on the disclosures set out in the Group's consolidated financial statements.

Details of impact of application of HKAS 7 Amendments – "Disclosure Initiative" are illustrated as below:

The Group shall apply these amendments for the first time in the current year. The amendments require an entity to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both cash and non-cash changes.

A reconciliation between opening and closing balances of liabilities arising from financing activities is set out in the consolidated financial statements. Consistent with the transition provisions of the amendments, the Group has not disclosed comparative information for the prior years.

### (b) Significant judgements and estimates

The preparation of the consolidated financial statements requires the directors of the Company to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The directors have considered the development, selection and disclosure of the Group's critical accounting judgements and estimates.

#### *Estimation uncertainties*

The key assumptions concerning the future and other key sources of estimation uncertainties at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (b) Significant judgements and estimates (Continued)

#### *Estimation uncertainties (Continued)*

Impairment on trade and bills receivables and other receivable

The provision policy for doubtful debts of the Group is based on the ongoing evaluation of the collectability and aged analysis of the outstanding receivables and on the directors' of the Company estimation. A considerable amount of judgement is required in assessing the ultimate realisation of these receivables, including the creditworthiness and the past collection history of each customer. If the financial conditions of the customers of the Group were to deteriorate, resulting in an impairment of their ability to make payments, additional impairment losses may be required.

### (c) Basis of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries for the year ended 31 March 2018. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described in the accounting policy for subsidiaries above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (d) Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than inventories, financial assets and goodwill), the asset's recoverable amount is estimated. An asset's recoverable amount is the higher of the asset's or cash-generating unit's value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

An impairment loss is recognised only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to the consolidated statement of profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognised impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognised impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of such an impairment loss is credited to the consolidated statement of profit or loss in the period in which it arises.

### (e) Related parties

A party is considered to be related to the Group if:

- (a) the party is a person or a close member of that person's family and that person
  - (i) has control or joint control over the Group;
  - (ii) has significant influence over the Group; or
  - (iii) is a member of the key management personnel of the Group or of a parent of the Group;

or

- (b) the party is an entity where any of the following conditions applies:
  - (i) the entity and the Group are members of the same group;
  - (ii) one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);
  - (iii) the entity and the Group are joint ventures of the same third party;

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (e) Related parties (Continued)

- (b) the party is an entity where any of the following conditions applies: (Continued)
  - (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;
  - (v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;
  - (vi) the entity is controlled or jointly controlled by a person identified in (a);
  - (vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and
  - (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

Close members of the family of a person are those family members who may be expected to influence, or be influenced by, that person in their dealings with the entity and include:

- (i) that person's children and spouse or domestic partner;
- (ii) children of that person's spouse or domestic partner; and
- (iii) dependents of that person or that person's spouse or domestic partner.

### (f) Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after the item has been put into operation, such as repairs and maintenance and overhaul costs, is normally charged to the consolidated income statement in the year in which it is incurred. In situations where it can be clearly demonstrated that the expenditure has resulted in an increase in future economic benefits expected to be obtained from the use of the item, the expenditure is capitalised as an additional cost of the item. When an item of property, plant and equipment is sold, its cost and accumulated depreciation are removed from the financial statements and any gain or loss resulting from the disposal, being the difference between the net disposal proceeds and the carrying amount of the asset, is included in the profit or loss.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (f) Property, plant and equipment and depreciation (Continued)

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

Leasehold improvements	Over the shorter of the lease terms and 20%
Furniture, fixtures and office equipment	20%
Computer equipment	20%
Plant and machinery	30%
Motor vehicles	30%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.

Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognised in the consolidated statement of profit or loss in the year the asset is derecognised is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress represents a building under construction, which is stated at cost less any impairment losses, and is not depreciated. Cost comprises the direct costs of construction and capitalised borrowing costs on related borrowed funds during the period of construction. Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

### (g) Leases

An arrangement, comprising a transaction or a series of transactions, is or contains a lease if the Group determines that the arrangement conveys a right to use a specific asset or assets for an agreed period of time in return for a payment or a series of payments. Such a determination is made based on an evaluation of the substance of the arrangement and is regardless of whether the arrangement takes the legal form of a lease.

#### (i) *Classification of assets leased to the Group*

Assets that are held by the Group under leases which transfer to the Group substantially all the risks and rewards of ownership are classified as being held under finance leases. Leases which do not transfer substantially all the risks and rewards of ownership to the Group are classified as operating leases.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (g) Leases (Continued)

#### (ii) *Assets acquired under finance leases*

Where the Group acquires the use of assets under finance leases, the amounts representing the fair value of the leased assets, or, if lower, the present value of the minimum lease payments of such assets, are included in property, plant and equipment and the corresponding liabilities, net of finance charges, are recorded as finance lease obligations. Depreciation is provided at rates which write off the cost of assets over the term of the relevant leases or, where it is likely the Group will obtain ownership of the assets, the life of the assets. Impairment losses are accounted for in accordance with the accounting policy as set out above. Finance charges implicit in the lease payments are charged to the consolidated statement of profit or loss over the period of the leases so as to produce an approximately constant periodic rate of charge on the remaining balance of the obligations for each accounting period. Contingent rentals, if any, are charged to the consolidated statement of profit or loss in the accounting period in which they are incurred.

#### (iii) *Operating lease charges*

Where the Group has the use of assets held under operating leases, payments made under the leases are charged to the consolidated statement of profit or loss in equal instalments over the accounting periods covered by the lease term, except where an alternative basis is more representative of the pattern of benefits to be derived from the leased assets. Lease incentives received are recognised in the consolidated statement of profit or loss as an integral part of the aggregate net lease payments made. Contingent rentals, if any, are charged to the consolidated statement of profit or loss in the accounting period in which they are incurred.

### (h) Investments and other financial assets

#### *Initial recognition and measurement*

The Group's financial assets are classified into loans and receivables and available-for-sale ("AFS") financial asset, which are recognised initially at fair value, plus transaction costs that are directly attributable to the acquisition of the financial assets.

The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (h) Investments and other financial assets (Continued)

#### *Effective interest method*

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest income is recognised on an effective interest basis for debt instruments.

#### *Subsequent measurement*

The subsequent measurement of financial assets depends on their classification as follows:

#### *Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial measurement, such assets (including trade receivables, deposits and other receivables, loan receivable, time deposits with original maturities of more than three months and cash and cash equivalents) are subsequently measured at amortised cost using the effective interest rate method less any allowance for impairment.

Interest income is recognised by applying the effective interest rate, except for short-term receivables where the recognition of interest would be immaterial.

#### *AFS financial assets*

AFS financial assets are non-derivative that are either designated as available-for-sale or are not classified as (a) loans and receivables, (b) held-to-maturity investments or (c) financial assets at fair value through profit or loss ("FVTPL").

Equity securities held by the Group that are classified as AFS financial asset and are traded in an active market are measured at fair value at the end of each reporting period. Dividends on AFS equity instruments are recognised in profit or loss when the Group's right to receive the dividends is established. Changes in the carrying amount of AFS financial assets are recognised in other comprehensive income and accumulated under the heading of assets revaluation reserve. When the investment is disposed of or is determined to be impaired, the cumulative gain or loss previously accumulated in the assets revaluation reserve is reclassified to profit or loss (see the accounting policy in respect of impairment loss on financial assets below).

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (i) Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's statement of financial position) when:

- the rights to receive cash flows from the asset have expired; or
- the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

### (j) Impairment of financial assets

The Group assesses at the end of each reporting period whether there is objective evidence that a financial asset or a group of financial assets is impaired. An impairment exists if one or more events that occurred after the initial recognition of the asset have an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.

For AFS equity investments, a significant or prolonged decline in the fair value of the security below its cost is considered to be objective evidence of impairment.

For all other financial assets, objective evidence of impairment could include:

- significant financial difficulty of the issuer or counterparty; or
- breach of contract, such as a default or delinquency in interest or principal payments; or
- it becoming probable that the borrower will enter bankruptcy or financial re-organisation; or
- disappearance of an active market for that financial asset because of financial difficulties.

Objective evidence of impairment for a portfolio of receivables could include the Group's past experience of collecting payments, an increase in the number of delayed payments in the portfolio past the average credit period ranging 30-90 days, observable changes in national or local economic conditions that correlate with default on receivables.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (j) Impairment of financial assets (Continued)

#### *Financial assets carried at amortised cost*

For financial assets carried at amortised cost, the Group first assesses whether impairment exists individually for financial assets that are individually significant, or collectively for financial assets that are not individually significant. If the Group determines that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, it includes the asset in a group of financial assets with similar credit risk characteristics and collectively assesses them for impairment. Assets that are individually assessed for impairment and for which an impairment loss is, or continues to be, recognised are not included in a collective assessment of impairment.

The amount of any impairment loss identified is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not yet been incurred). The present value of the estimated future cash flows is discounted at the financial asset's original effective interest rate (i.e., the effective interest rate computed at initial recognition).

The carrying amount of the asset is reduced through the use of an allowance account and the loss is recognised in the consolidated statement of profit or loss. Interest income continues to be accrued on the reduced carrying amount using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. Loans and receivables together with any associated allowance are written off when there is no realistic prospect of future recovery and all collateral has been realised or has been transferred to the Group.

If, in a subsequent period, the amount of the estimated impairment loss increases or decreases because of an event occurring after the impairment was recognised, the previously recognised impairment loss is increased or reduced by adjusting the allowance account. If a write-off is later recovered, the recovery is credited to other expenses in the consolidated statement of profit or loss.

### (k) Financial liabilities and equity instruments

#### *Initial recognition and measurement*

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.

The Group's financial liabilities include trade payables, other payables and accruals, amounts due to related companies, amounts due to directors of the Company, finance leases payables and liability component of convertible bonds. They are subsequently measured at amortised cost, using the effective interest method.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (k) Financial liabilities and equity instruments (Continued)

#### *Subsequent measurement*

The subsequent measurement of financial liabilities depends on their classification as follows:

#### *Loans and borrowings*

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in the consolidated statement of profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in finance costs in the consolidated statement of profit or loss.

#### *Convertible bonds*

The component parts of compound instruments (convertible bonds) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company's own equity instruments is an equity instrument.

At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. The liability component is measured on an amortised cost basis at subsequent reporting dates using the effective interest method until extinguished upon conversion or at the instrument's maturity date.

The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in equity, net of income tax effects, and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity until the conversion option is exercised, in which case, the balance recognised in equity will be transferred to share premium. When the conversion option remains unexercised at the maturity date of the convertible bonds, the balance recognised in equity will be transferred to retained profits. No gain or loss is recognised in profit or loss upon conversion or expiration of the conversion option.

Transaction costs that relate to the issue of the convertible bonds are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognised directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortised over the lives of the convertible bonds using the effective interest method.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (k) Financial liabilities and equity instruments (Continued)

#### *Equity instruments*

An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities. Equity instruments issued by the Company are recognised at the proceeds received, net of direct issue costs.

#### *Effective interest method*

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Interest expense is recognised on an effective interest basis.

### (l) Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in the consolidated statement of profit or loss.

### (m) Provisions

A provision is recognised when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognised for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in the consolidated statement of profit or loss.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (n) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the first-in, first-out basis and, in the case of work in progress and finished goods, comprises direct materials, direct labour and an appropriate proportion of overheads. Net realisable value is based on estimated selling prices less any estimated costs expected to be incurred to completion and disposal.

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

### (o) Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired, less bank overdrafts which are repayable on demand and form an integral part of the Group's cash management.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including time deposits with original maturity of less than three months, which are not restricted as to use.

### (p) Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognised outside profit or loss is recognised outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (p) Income tax (Continued)

Deferred tax assets are recognised for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carryforward of unused tax credits and unused tax losses can be utilised, except:

- when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at the end of each reporting period and are recognised to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

### (q) Government grants

Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the costs, which it is intended to compensate, are expensed.

Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to the consolidated statement of profit or loss over the expected useful life of the relevant asset by equal annual instalments or deducted from the carrying amount of the asset and released to the consolidated statement of profit or loss by way of a reduced depreciation charge.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (r) Revenue recognition

Revenue is recognised when it is probable that the economic benefits will flow to the Group and when the revenue can be measured reliably, on the following bases:

- (i) from the sale of goods, when the significant risks and rewards of ownership have been transferred to the buyer, provided that the Group maintains neither managerial involvement to the degree usually associated with ownership, nor effective control over the goods sold;
- (ii) rental income, on a time proportion basis over the lease terms;
- (iii) franchise income, on a time proportion basis based on the terms of the underlying franchise agreements; and
- (iv) interest income, on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

### (s) Share-based payments

The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments ("equity-settled transactions").

The cost of equity-settled transactions with employees for grants after 17 August 2012 is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 25 to the financial statements.

The cost of equity-settled transactions is recognised in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognised for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the consolidated statement of profit or loss for a period represents the movement in the cumulative expense recognised as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (s) Share-based payments (Continued)

For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognised. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognised for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of modification.

Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. This includes any award where non-vesting conditions within the control of either the Group or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of earnings per share.

### (t) Other employee benefits

#### (i) Pension scheme

The Group operates a defined contribution Mandatory Provident Fund retirement benefit scheme (the "MPF Scheme") under the Mandatory Provident Fund Schemes Ordinance for all those employees who are eligible to participate in the MPF Scheme. Contributions are made based on a percentage of the participating employees' basic salaries and are charged to the consolidated statement of profit or loss as they become payable in accordance with the rules of the MPF Scheme. The assets of the MPF Scheme are held separately from those of the Group in an independently administered fund. The Group's employer contributions vest fully with the employees when contributed into the MPF Scheme.

The employees of the Group's subsidiaries which operate in the PRC are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a certain percentage of the payroll costs to the central pension scheme. The contributions are charged to the consolidated statement of profit or loss as they become payable in accordance with the rules of the central pension scheme.

#### (ii) Employee leave entitlement

Employee entitlements to annual leave are recognised when they accrue to employees. An accrual is made for the estimated liability for annual leave as a result of services rendered by employees up to the end of the reporting period.

#### (iii) Employee long service payment

The provision for long service is provided based on the employees' basic salaries and their respective length of service in accordance with the applicable rules and regulations in their respective countries of employment.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (u) Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets. The capitalisation of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalised. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

### (v) Foreign currencies

These consolidated financial statements are presented in Hong Kong dollars, which is the Company's functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognised in the consolidated statement of profit or loss.

Differences arising on settlement or translation of monetary items are recognised in the consolidated statement of profit or loss with the exception of monetary items that are designated as part of the hedge of the Group's net investment of a foreign operation. These are recognised in other comprehensive income until the net investment is disposed of, at which time the cumulative amount is reclassified to the consolidated statement of profit or loss. Tax charges and credits attributable to exchange differences on those monetary items are also recorded in other comprehensive income.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognised in other comprehensive income or profit or loss is also recognised in other comprehensive income or profit or loss, respectively).

The functional currencies of certain overseas subsidiaries are currencies other than the Hong Kong dollar. As at the end of the reporting period, the assets and liabilities of these entities are translated into Hong Kong dollars at exchange rates prevailing at the end of the reporting period and their statements of profit or loss are translated into Hong Kong dollars at the weighted average exchange rates for the year.

The resulting exchange differences are recognised in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognised in the consolidated statement of profit or loss.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 2. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND PRINCIPAL ACCOUNTING POLICIES (Continued)

### (v) Foreign currencies (Continued)

For the purpose of the consolidated statement of cash flows, the cash flows of overseas subsidiaries are translated into Hong Kong dollars at the exchange rates ruling at the dates of the cash flows. Frequently recurring cash flows of overseas subsidiaries which arise throughout the year are translated into Hong Kong dollars at the weighted average exchange rates for the year.

### (w) Segment reporting

Operating segments, and the amounts of each segment item reported in the consolidated financial statements, are identified from the financial information provided regularly to the Group's most senior executive management for the purposes of allocating resources to, and assessing the performance of, the Group's various lines of business and geographical locations.

Individually material operating segments are not aggregated for financial reporting purposes unless the segments have similar economic characteristics and are similar in respect of the nature of products and services, the nature of production processes, the type or class of customers, the methods used to distribute the products or provide the services, and the nature of the regulatory environment. Operating segments which are not individually material may be aggregated if they share a majority of these criteria.

## 3. SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments as follows:

- (a) the "Distribution of pharmaceutical products" segment engages in the trading and distribution of pharmaceutical products; and
- (b) the "Distribution of tea and other food products" segment engages in the trading and distribution of tea and other food products.

Directors monitor the results of the Group's operating segments separately for the purpose of making decisions about resources allocation and performance assessment. Segment performance is evaluated based on reportable segment (loss)/profit, which represents the loss from/profit earned by each segment without allocation of bank interest income, interest income from loan receivable, finance costs, write off of items of property, plant and equipment, gain on disposal of items of property, plant and equipment, equity-settled share option expense, exchange gain as well as head office and corporate expenses.

Segment assets exclude available-for-sale financial assets, time deposits with original maturities of more than three months, cash and cash equivalents and other unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude finance leases payables, convertible bonds, income tax payables and other unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 3. SEGMENT INFORMATION (Continued)

### (a) Operating segments

	Distribution and trading of pharmaceutical products HK\$'000	Distribution and trading of tea and other food products HK\$'000	Total HK\$'000
<b>Year ended 31 March 2018</b>			
<b>Segment revenue:</b>			
Sales to external customers	4,642	77,028	81,670
Other income	102	2,200	2,302
	<b>4,744</b>	<b>79,228</b>	<b>83,972</b>
<b>Segment results</b>	<b>(6,838)</b>	<b>(4,263)</b>	<b>(11,101)</b>
<i>Reconciliation:</i>			
Bank interest income			1,299
Interest income from loan receivable			683
Gain on disposal of items of property, plant and equipment, net			58
Corporate and other unallocated expenses			(14,501)
Finance costs			(10,325)
Loss before tax			(33,887)
<b>As at 31 March 2018</b>			
<b>Segment assets</b>	<b>3,060</b>	<b>37,211</b>	<b>40,271</b>
<i>Reconciliation:</i>			
Available-for-sale financial assets			7,500
Time deposits with original maturities of more than three months			96,313
Cash and cash equivalents			153,336
Corporate and other unallocated assets			226
Total assets			297,646
<b>Segment liabilities</b>	<b>1,519</b>	<b>38,797</b>	<b>40,316</b>
<i>Reconciliation:</i>			
Convertible bonds			58,767
Finance leases payables			467
Income tax payables			2
Corporate and other unallocated liabilities			13,884
Total liabilities			113,436
<b>Year ended 31 March 2018</b>			
<b>Other segment information:</b>			
Impairment losses recognised on inventories in the consolidated statement of profit or loss	10	–	10
Impairment losses recognised on trade receivables in the consolidated statement of profit or loss	–	2,819	2,819
Impairment losses reversed on trade receivables in the consolidated statement of profit or loss	–	(2,730)	(2,730)
Impairment losses reversed on other receivables in the consolidated statement of profit or loss	–	(68)	(68)
Depreciation	544	501	1,045
Capital expenditure*	239	483	722

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 3. SEGMENT INFORMATION (Continued)

### (a) Operating segments (Continued)

	Distribution and trading of pharmaceutical products HK\$'000	Distribution and trading of tea and other food products HK\$'000	Total HK\$'000
Year ended 31 March 2017			
<b>Segment revenue:</b>			
Sales to external customers	5,829	117,861	123,690
Other income	20	4,062	4,082
	5,849	121,923	127,772
<b>Segment results</b>	(6,421)	(11,057)	(17,478)
<i>Reconciliation:</i>			
Bank interest income			2,324
Interest income from loan receivable			5,863
Write off of items of property, plant and equipment			(383)
Gain on disposal of items of property, plant and equipment, net			168
Equity-settled share option expense			(6,311)
Corporate and other unallocated expenses			(14,708)
Finance costs			(1,652)
Exchange gain			10
Loss before tax			(32,167)
As at 31 March 2017			
<b>Segment assets</b>	3,488	195,862	199,350
<i>Reconciliation:</i>			
Time deposits with original maturities of more than three months			30,593
Cash and cash equivalents			111,439
Corporate and other unallocated assets			298
Total assets			341,680
<b>Segment liabilities</b>	1,973	69,073	71,046
<i>Reconciliation:</i>			
Convertible bonds			52,032
Finance leases payables			876
Corporate and other unallocated liabilities			13,450
Total liabilities			137,404
Year ended 31 March 2017			
<b>Other segment information:</b>			
Impairment losses recognised in the consolidated statement of profit or loss	86	18,275	18,361
Impairment losses reversed in the consolidated statement of profit or loss	–	(1,459)	(1,459)
Depreciation	656	758	1,414
Capital expenditure*	628	367	995

\* Capital expenditure consists of additions to property, plant and equipment.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 3. SEGMENT INFORMATION (Continued)

### (b) Geographical information

(i) Revenue from external customers:

	2018 HK\$'000	2017 HK\$'000
The People Republic of China ("the PRC"), excluding Hong Kong	72,154	113,397
Hong Kong	4,642	5,722
Elsewhere in Asia	1,798	3,230
United States of America	3,076	1,341
	<b>81,670</b>	123,690

The revenue information above is based on the location of the customers.

(ii) Non-current assets:

	2018 HK\$'000	2017 HK\$'000
The PRC, excluding Hong Kong	1,705	1,558
Hong Kong	696	1,008
	<b>2,401</b>	2,566

The non-current asset information above is based on the location of the assets.

### (c) Information about major customers

None of the customer contributed 10% or more sales to the Group's revenue for the year ended 31 March 2018.

Revenue of approximately HK\$27,548,000 for the year ended 31 March 2017 was derived from sales to two major customers. Each of these customers contributed 10% or more sales to the Group's revenue.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 4. REVENUE AND OTHER INCOME

Revenue represents the net invoiced value of goods sold, after allowances for returns and trade discounts, during the year.

An analysis of revenue and other income is as follows:

	2018 HK\$'000	2017 HK\$'000
<b>Revenue</b>		
Sale of goods	81,670	123,690
<b>Other income</b>		
Franchise income	1,583	1,528
Bank interest income	1,299	2,324
Subsidy income <sup>^</sup>	406	2,223
Rental income	144	140
Exchange gain	–	10
Others	169	191
	<b>3,601</b>	<b>6,416</b>

<sup>^</sup> Various one-off government subsidies are provided regarding the expenditures incurred by the Group's subsidiaries regarding as "high and new technology enterprises" in Yunnan province, the PRC which had been already expensed in profit or loss. There are no unfulfilled conditions or contingencies related to these subsidies.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 5. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	<i>Notes</i>	<b>2018</b> <b>HK\$'000</b>	2017 HK\$'000
Cost of inventories recognised as an expense		<b>46,496</b>	71,412
Depreciation	12	<b>1,045</b>	1,414
Minimum lease payments under operating leases of offices and shops premises		<b>8,305</b>	10,425
Auditors' remuneration			
– Audit services		<b>930</b>	1,930
– Non-audit services		<b>338</b>	300
Employee benefits expense (excluding directors' remuneration):			
Salaries, allowances and benefits in kind		<b>22,420</b>	26,460
Pension scheme contributions		<b>2,190</b>	4,772
Equity-settled share option expense <sup>^</sup>		–	1,629
		<b>24,610</b>	32,861
Provision for slow-moving and obsolete inventories <sup>*</sup>	14	<b>10</b>	101
Exchange gain <sup>#</sup>		–	(10)
Impairment losses of trade receivables <sup>®</sup>	15	<b>2,819</b>	18,142
Write off of items of property, plant and equipment <sup>®</sup>	12	–	383
Impairment losses of other receivables <sup>®</sup>	16	–	118
Reversal of impairment losses of trade receivables <sup>®</sup>	15	<b>(2,730)</b>	(1,459)
Reversal of impairment losses of other receivables <sup>®</sup>	16	<b>(68)</b>	–

\* Included in the "Cost of sales" in the consolidated statement of profit or loss.

# Included in the "Other income" in the consolidated statement of profit or loss.

® Included in the "Other expenses" in the consolidated statement of profit or loss.

<sup>^</sup> The amount is related to share options granted to employees of the Company.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 6. FINANCE COSTS

	Notes	2018 HK\$'000	2017 HK\$'000
Interest on finance leases	27	26	38
Effective interest expense on Convertible Bonds	22 & 27	10,299	1,614
		<b>10,325</b>	1,652

## 7. DIRECTORS' AND CHIEF EXECUTIVE'S REMUNERATION

Directors' and chief executive's remuneration for the year, disclosed pursuant to the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), section 383(1)(a), (b), (c) and (f) of the Hong Kong Companies Ordinance and Part 2 of the Companies (Disclosure of Information about Benefits of Directors) Regulation, is as follows:

	2018 HK\$'000	2017 HK\$'000
Fees:		
Executive directors	10	10
Independent non-executive directors	480	368
	<b>490</b>	378
Other emoluments:		
Salaries, allowances and benefits in kind	5,754	5,544
Pension scheme contributions	54	51
Equity-settled share option expense	–	4,682
	<b>5,808</b>	10,277
	<b>6,298</b>	10,655

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 7. DIRECTORS' AND CHIEF EXECUTIVE'S REMUNERATION (Continued)

### (a) Independent non-executive directors

	Director fee HK\$'000	Salaries, allowances and benefits in kind HK\$'000	Pension scheme contributions HK\$'000	Equity- settled share option expense HK\$'000 <i>(note)</i>	Total remuneration HK\$'000
<b>Year ended 31 March 2018</b>					
Mr. Guo Guoqing	120	-	-	-	120
Mr. Lam Siu Hung	120	-	-	-	120
Mr. Kwok Hok Lun	120	-	-	-	120
Dr. Liu Zhonghua	120	-	-	-	120
	<b>480</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>480</b>
<b>Year ended 31 March 2017</b>					
Mr. Guo Guoqing	92	-	-	132	224
Mr. Lam Siu Hung	92	-	-	132	224
Mr. Kwok Hok Lun	92	-	-	132	224
Dr. Liu Zhonghua	92	-	-	132	224
	<b>368</b>	<b>-</b>	<b>-</b>	<b>528</b>	<b>896</b>

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 7. DIRECTORS' AND CHIEF EXECUTIVE'S REMUNERATION (Continued)

### (b) Executive directors

	Director fee HK\$'000	Salaries, allowances and benefits in kind HK\$'000	Pension scheme contributions HK\$'000	Equity- settled share option expense HK\$'000 <i>(note)</i>	Total remuneration HK\$'000
<b>Year ended 31 March 2018</b>					
Dr. Chiu Ka Leung	10	2,340	18	–	2,368
Ms. Yeh Shu Ping*	–	1,950	–	–	1,950
Mr. Jiao Shaoliang	–	624	18	–	642
Dr. He William (also known as Lu Pingguo)	–	840	18	–	858
	<b>10</b>	<b>5,754</b>	<b>54</b>	<b>–</b>	<b>5,818</b>
<b>Year ended 31 March 2017</b>					
Dr. Chiu Ka Leung	10	2,322	18	185	2,535
Ms. Yeh Shu Ping*	–	1,950	–	1,323	3,273
Mr. Jiao Shaoliang	–	606	18	1,323	1,947
Dr. He William (also known as Lu Pingguo)	–	666	15	1,323	2,004
	<b>10</b>	<b>5,544</b>	<b>51</b>	<b>4,154</b>	<b>9,759</b>

\* Ms. Yeh Shu Ping, an executive director of the Company, was also the chief executive of the Company for both years.

*Note:* The amounts above represent the estimated value of the non-cash share options granted to the executive directors and independent non-executive directors under the Company's share option scheme. These amounts are based on the Group's accounting policies for equity-settled share-based payment transaction as set out in note 2(s). Details of the principal terms and number of options granted, are disclose in note 25.

There was no arrangement under which a director or the chief executive waived or agreed to waive any remuneration during the year (2017: Nil).

Salaries, allowance and benefits in kind paid to or for the executive director are generally emoluments paid or payable in respect of those persons' other services in connection with the management of the affairs of the Company and its subsidiaries.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 8. FIVE HIGHEST PAID EMPLOYEES

The five highest paid employees during the year included two (2017: three) directors, details of whose remuneration are set out in note 7 above. Details of the remuneration for the year of the remaining three (2017: two) highest paid employees who are neither a director nor chief executive of the Company are as follows:

	2018 HK\$'000	2017 HK\$'000
Salaries, allowances and benefits in kind	3,966	3,609
Equity-settled share option expense	–	1,356
Pension scheme contributions	54	36
	<b>4,020</b>	<b>5,001</b>

The number of non-director highest paid employees whose remuneration fell within the following bands is as follows:

	Number of employees	
	2018	2017
Nil to HK\$1,000,000	–	–
HK\$1,000,001 to HK\$2,000,000	3	–
HK\$2,000,001 to HK\$3,000,000	–	2
	<b>3</b>	<b>2</b>

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 9. INCOME TAX EXPENSE

No provision for Hong Kong profits tax has been made as the Company and its subsidiaries do not generate any assessable profits arising in Hong Kong during the current year (2017: Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profit). Under the Law of the People's Republic of China on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% for both years. Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the jurisdictions in which the Group operates, based on existing legislation, interpretations and practices in respect thereof.

	2018 HK\$'000	2017 HK\$'000
Current – Hong Kong		
Underprovision in prior years	–	1
	–	1
Current – PRC Enterprise Income Tax		
Charge for the year	15	17
Underprovision in prior years	–	246
	15	263
Total income tax expense for the year	15	264

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 9. INCOME TAX EXPENSE (Continued)

A reconciliation of the income tax expense applicable to loss before tax at the statutory rates for the jurisdictions in which the Company and the majority of its subsidiaries are domiciled to the tax expense at the effective tax rates, and a reconciliation of the applicable rates (i.e., the statutory tax rates) to the effective tax rates, are as follows:

	Hong Kong, British Virgin Islands and Cayman Islands		The PRC		Total	
	HK\$'000	%	HK\$'000	%	HK\$'000	%
<b>Year ended 31 March 2018</b>						
Loss before tax	(30,804)	–	(3,083)	–	(33,887)	–
Tax at the statutory or applicable tax rate	(5,083)	16.5	(771)	25.0	(5,854)	17.3
Income tax at preferential tax rate	–	–	(17)	0.6	(17)	–
Deductible temporary differences not recognised	–	–	27	(0.9)	27	(0.1)
Utilisation of deductible temporary differences previously not recognised	(2)	–	–	–	(2)	–
Income not subject to tax	(313)	1.0	(487)	15.8	(800)	2.4
Expenses not deductible for tax	4,437	(14.4)	1,403	(45.5)	5,840	(17.2)
Utilisation of tax losses previously not recognised	–	–	(605)	19.6	(605)	1.8
Tax losses not recognised	972	(3.2)	464	(15.1)	1,436	(4.2)
Others	(11)	0.1	1	–	(10)	–
Tax at the Group's effective rate	–	–	15	(0.5)	15	–
<b>Year ended 31 March 2017</b>						
Loss before tax	(28,435)	–	(3,732)	–	(32,167)	–
Tax at the statutory or applicable tax rate	(4,692)	16.5	(933)	25.0	(5,625)	17.5
Income tax at preferential tax rate	–	–	275	(7.4)	275	(0.8)
Adjustments in respect of current tax of previous periods	1	–	246	(6.6)	247	(0.8)
Income not subject to tax	(80)	0.3	–	–	(80)	0.2
Expenses not deductible for tax	3,724	(13.1)	1,159	(31.0)	4,883	(15.2)
Utilisation of tax losses previously not recognised	–	–	(613)	16.4	(613)	2.0
Tax losses not recognised	1,055	(3.7)	129	(3.4)	1,184	(3.7)
Others	(7)	–	–	–	(7)	–
Tax at the Group's effective rate	1	–	263	(7.0)	264	(0.8)

# Notes to the Consolidated Financial Statements (Continued)

*For the year ended 31 March 2018*

## 9. INCOME TAX EXPENSE (Continued)

In accordance with the relevant tax rules and regulations in the PRC, a subsidiary of the Company in the PRC enjoys tax benefit as follows:

YNLR, a subsidiary of the Company in the PRC, is qualified as High and New Technology Enterprise which is entitled to a reduced preferential EIT rate of 15% for a 3-year period from 31 July 2015 to 30 July 2018, according to the Detailed Implementation Rules of the EIT Law.

## 10. DIVIDEND

The directors of the Company do not recommend the payment of any dividend for the year ended 31 March 2018 (2017: Nil).

## 11. LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

The calculation of the basic loss per share amount is based on the loss for the year attributable to owners of the Company of approximately HK\$33,902,000 (2017: HK\$32,431,000), and the weighted average number of ordinary shares of approximately 1,451,520,000 (2017: 1,450,161,000) in issue during the year.

For both years ended 31 March 2018 and 2017, the computation of diluted loss per share does not assume the conversion of the Company's outstanding convertible bonds and exercise of outstanding share options since their assumed exercises would result in a decrease in loss per share.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 12. PROPERTY, PLANT AND EQUIPMENT

	Leasehold improvements HK\$'000	Furniture, fixtures and office equipment HK\$'000	Computer equipment HK\$'000	Plant and machinery HK\$'000	Motor vehicles HK\$'000	Total HK\$'000
<b>31 March 2018</b>						
At 1 April 2017:						
Cost	2,512	1,449	753	1,101	2,136	7,951
Accumulated depreciation and impairment	(1,819)	(757)	(718)	(1,101)	(990)	(5,385)
Net carrying amount	693	692	35	–	1,146	2,566
At 1 April 2017, net of accumulated depreciation and impairment	693	692	35	–	1,146	2,566
Additions	–	290	26	–	406	722
Disposals	–	–	(8)	–	–	(8)
Depreciation provided during the year	(192)	(247)	(12)	–	(594)	(1,045)
Exchange realignment	64	75	–	–	27	166
At 31 March 2018, net of accumulated depreciation and impairment	565	810	41	–	985	2,401
At 31 March 2018:						
Cost	2,610	1,851	728	1,101	2,351	8,641
Accumulated depreciation and impairment	(2,045)	(1,041)	(687)	(1,101)	(1,366)	(6,240)
Net carrying amount	565	810	41	–	985	2,401

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 12. PROPERTY, PLANT AND EQUIPMENT (Continued)

	Leasehold improvements HK\$'000	Furniture, fixtures and office equipment HK\$'000	Computer equipment HK\$'000	Plant and machinery HK\$'000	Motor vehicles HK\$'000	Total HK\$'000
31 March 2017						
At 1 April 2016:						
Cost	2,957	1,998	725	1,101	2,342	9,123
Accumulated depreciation and impairment	(1,753)	(806)	(693)	(1,101)	(1,266)	(5,619)
Net carrying amount	1,204	1,192	32	–	1,076	3,504
At 1 April 2016, net of accumulated depreciation and impairment	1,204	1,192	32	–	1,076	3,504
Additions	208	131	28	–	628	995
Write off	(105)	(278)	–	–	–	(383)
Depreciation provided during the year	(555)	(291)	(25)	–	(543)	(1,414)
Exchange realignment	(59)	(62)	–	–	(15)	(136)
At 31 March 2017, net of accumulated depreciation and impairment	693	692	35	–	1,146	2,566
At 31 March 2017:						
Cost	2,512	1,449	753	1,101	2,136	7,951
Accumulated depreciation and impairment	(1,819)	(757)	(718)	(1,101)	(990)	(5,385)
Net carrying amount	693	692	35	–	1,146	2,566

The net carrying amount of the Group's fixed assets held under finance leases included in the total amount of motor vehicles at 31 March 2018 amounted to approximately HK\$472,000 (2017: HK\$954,000).

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 13. AVAILABLE-FOR-SALE FINANCIAL ASSETS

The available-for-sale financial assets represent investments in equity securities listed on The Stock Exchange of Hong Kong Limited, which are measured at fair value at the end of the reporting period and the fair value measurement is categorized as Level 1 under fair value measurement category under HKFRS 13.

## 14. INVENTORIES

	2018 HK\$'000	2017 HK\$'000
Trading goods	1,689	2,952
Finished goods	175	457
Work in progress	65	90
Raw materials	68	287
Packaging materials	122	188
	<b>2,119</b>	3,974

During the year ended 31 March 2018, the amount of write down of inventories to their net realisable value of approximately HK\$10,000 (2017: HK\$101,000) was recognised as an expense in the consolidated statement of profit or loss.

## 15. TRADE RECEIVABLES

	2018 HK\$'000	2017 HK\$'000
Trade receivables	50,094	46,175
Less: impairment losses	(23,084)	(20,783)
	<b>27,010</b>	25,392

The Group's trading terms with its customers are mainly on credit, except for new customers of which payment in advance is normally required. The credit period generally ranges from 30 to 90 days (2017: 30 to 90 days). Due to the continuous slowdown in traditional retail sales of the consumer goods in the PRC resulted from gradually deceleration of the economic development in the PRC in recent years, the discouragement of excessive hospitality such as gifting by the PRC government and the consolidation and enhanced regulation of the PRC direct selling industry, operating performances of certain customers were adversely affected and these customers are in financial difficulties so that proportion of long aged trade receivables increased during the year. Accordingly, the Group seeks to maintain strict control over its outstanding receivables. Regarding those major customers, the Group uses an internal credit rating system to assess those customers' credit qualities, defines credit limits by customer and performs follow up procedures on settlements of outstanding receivables. Overdue balances are reviewed regularly by the directors of the Company and impairment of trade receivables are provided to trade receivables that are overdue over 3 months and without settlements during the reporting period and subsequent to the end of the reporting period. Trade receivables are non-interest-bearing.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 15. TRADE RECEIVABLES (Continued)

An aged analysis of the trade receivables, net of impairment losses as at the end of the reporting period, based on the invoice dates, is as follows:

	2018 HK\$'000	2017 HK\$'000
Within 1 month	4,859	5,676
2 to 3 months	6,429	8,056
4 to 12 months	14,580	10,481
Over 12 months	1,142	1,179
	<b>27,010</b>	25,392

An aged analysis of the trade receivables as at the end of the reporting period, based on the payment due date, that are not individually nor collectively considered to be impaired is as follows:

	2018 HK\$'000	2017 HK\$'000
Current (neither past due nor impaired)	5,148	6,249
Within 1 to 3 months overdue	6,140	12,193
Within 4 to 12 months overdue	15,722	6,950
	<b>27,010</b>	25,392

The movements in the provision for impairment losses of trade receivables are as follows:

	<i>Note</i>	2018 HK\$'000	2017 HK\$'000
At beginning of year		20,783	4,745
Impairment losses recognised	5	2,819	18,142
Impairment losses reversed	5	(2,730)	(1,459)
Amounts written off as uncollectible		(11)	–
Exchange realignment		2,223	(645)
At end of year		<b>23,084</b>	20,783

Included in the above provision for impairment of the trade receivables are individually impaired trade receivables with an aggregate balance of HK\$23,084,000 (2017: HK\$20,783,000). These individually impaired receivables are related to customers that are in financial difficulties and the directors of the Company assessed that the chance of recoverability is remote.

Receivables that are past due but not impaired are related to a number of individual customers that have good track records with the Group. Based on past experience, the directors of the Company are of the opinion that no provision for impairment is necessary in respect of these balances as there are no significant change in credit quality of the balances and the balances are still considered to be fully recoverable. The Group does not hold any collateral over these balances.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 15. TRADE RECEIVABLES (Continued)

Included in the Group's trade receivables are trade receivables due from 理想科技集團有限公司 (Ideality Technology Group Company Limited)\* (the "Ideality Group"), a related party of the Group which is beneficially owned as to 85.5% and 14.5% by Dr. Chiu Ka Leung ("Dr. Chiu") and Mr. Jiao Shaoliang ("Mr. Jiao"), respectively. Both Dr. Chiu and Mr. Jiao are executive directors and shareholders of the Company, while Dr. Chiu is also a substantial shareholder of the Company (*note 31(a)(i)*), of approximately HK\$5,329,000 (2017: HK\$6,941,000), which are repayable on similar credit terms to those offered to the major customers of the Group. Included in the balances due from Ideality Group, there are approximately HK\$2,350,000 (2017: HK\$4,126,000) which are past due at the end of the reporting period. Based on past experience, the directors of the Company determine that no provision for impairment is necessary in respect of these balances as there are no significant change in credit quality of the balances and most of these balances as at 31 March 2018 are settled subsequent to the end of the reporting period.

## 16. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	2018 HK\$'000	2017 HK\$'000
Prepayments for rental and advertising expenses	3,132	566
Deposits and other receivables ( <i>note</i> )	6,013	6,324
Less: impairment losses	(178)	(229)
	<b>8,967</b>	6,661

*Note:* Deposits and other receivables mainly comprised of rental and utility charges deposits and advances to staff.

The movements in the provision for impairment of prepayment, deposits and other receivables are as follows:

	<i>Note</i>	2018 HK\$'000	2017 HK\$'000
At beginning of year		229	120
Impairment loss recognised	5	–	118
Impairment loss reversed	5	(68)	–
Exchange realignment		17	(9)
At end of year		<b>178</b>	229

Included in the above provision for impairment of the prepayments, deposits and other receivables is a provision for individually impaired prepayments, deposits and other receivables with an aggregate balance of approximately HK\$178,000 (2017: HK\$229,000). These individually impaired receivables are related to staff advances that are long outstanding and the directors of the Company assessed that the chance of recoverability is remote.

\* Official name of this entity is in Chinese. The English translation of the name is for identification purpose only.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 17. LOAN RECEIVABLE

	2018 HK\$'000	2017 HK\$'000
Fixed-rate loan receivable	–	155,138
Interest receivable on loan receivable	–	5,917
Amount due within 1 year shown as current asset	–	161,055

The loan receivable was granted to a party (“Borrower”) which is an independent third party of the Group or any of the directors of the Company. The loan receivable was denominated in RMB, which was unsecured, interest-bearing at fixed rate of 9% per annum and would be repayable within 6 months after the available date of releasing advance as prescribed in the loan agreement, which was approved by the directors of the subsidiary of the Group. The loan was paid to FLRT, CLRT and YLRP (as defined in notes 19, 31(a)(ii)&(iii) and 31(b)(i)) at the instruction of the borrower. The loan interest income of approximately HK\$683,000 (2017: HK\$5,863,000) was recognised as the “Interest income from loan receivable” in the consolidated statement of profit or loss. At 31 March 2017, the loan and interest receivable have been past due and repayable on demand. During the year ended 31 March 2018, the loan receivable and interest thereon are fully repaid by the borrower and LRTG (as defined in notes 19 and 31(a)(ii)) at the instruction of the borrower. Details of loan receivable are set out in the announcement of the Company dated 28 February 2018.

## 18. CASH AND CASH EQUIVALENTS

	2018 HK\$'000	2017 HK\$'000
Cash and bank balances	153,336	21,218
Time deposits with original maturities of less than three months	–	90,221
Cash and cash equivalents	153,336	111,439

At the end of the reporting period, the cash and cash equivalents of the Group denominated in RMB amounted to approximately HK\$142,624,000 (2017: HK\$3,521,000) while the remaining cash and cash equivalents are denominated in HK\$. The RMB is not freely convertible into other currencies, however, under Mainland China’s Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

The Group’s time deposits with original maturities of more than three months are denominated in HK\$ at 31 March 2018 (2017: HK\$).

Cash at banks earns interest at floating rates based on daily bank deposit rates which range from 0.01% to 1.38% (2017: 0.01% to 1.1%) per annum. Short term time deposits are made for varying periods of between one day and three months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The bank balances and time deposits are deposited with creditworthy banks with no recent history of default. The carrying amounts of the cash and cash equivalents and the time deposits approximate to their fair values.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 19. TRADE PAYABLES

The trade payables are non-interest-bearing and are normally settled on 90-day terms.

An aged analysis of the trade payables as at the end of the reporting period, based on the payment due date, is as follows:

	2018 HK\$'000	2017 HK\$'000
Current and not past due	1,176	9,535
Within 1 to 3 months overdue	2	11,585
Within 4 to 12 months overdue	–	731
Over 12 months overdue	483	532
	<b>1,661</b>	<b>22,383</b>

Included in the Group's trade payables are trade payables due to the following related parties:

	2018 HK\$'000	2017 HK\$'000
Yunnan Longrun Tea Group Company Limited <sup>®</sup> ("LRTG") 雲南龍潤茶業集團有限公司	646	7,779
Fengqing Longrun Tea Company Limited <sup>®</sup> ("FLRT") 鳳慶龍潤茶業有限公司	397	6,721
Changning Longrun Tea Company Limited <sup>®</sup> ("CLRT") 昌寧縣龍潤茶業有限公司	128	7,038
Yunnan Longfar Pharmaceutical Company Limited <sup>®</sup> ("YNLF") 雲南龍發製藥股份有限公司 (前稱「雲南龍發製藥有限公司」)	33	316
	<b>1,204</b>	<b>21,854</b>

Details of relationships with the Group regarding the aforesaid related parties are disclosed in note 31(a)(ii)-(v). The trade payables due to related parties are non-interest bearing and are normally settled on 90-day terms.

\* Official names of these entities are in Chinese. The English translation of these names is for identification purpose only.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 20. OTHER PAYABLES, ACCRUALS AND RECEIPTS IN ADVANCE

	2018 HK\$'000	2017 HK\$'000
Receipts in advance from customers	18,706	27,646
Accruals	26,284	25,103
Other payables	3,445	3,298
	<b>48,435</b>	56,047

Included in the Group's other payables is the other payable due to YLRT, a related party of the Group, of approximately HK\$131,000 (2017: HK\$592,000). The balance is unsecured, interest free and repayable on demand.

## 21. FINANCE LEASES PAYABLES

The Group leases certain of its motor vehicles (*Note 12*) under finance leases for manufacturing and distribution of its pharmaceutical products business. The lease terms of finance leases payables are ranging from 3 to 5 years (2017: 3 to 5 years).

At 31 March 2018, the total future minimum lease payments under finance leases and its present values were as follows:

	Minimum lease payments 2018 HK\$'000	Minimum lease payments 2017 HK\$'000	Present value of minimum lease payments 2018 HK\$'000	Present value of minimum lease payments 2017 HK\$'000
Amounts payable:				
Within one year	280	435	267	409
In the second year	124	280	118	267
In the third to fifth years	83	207	82	200
Total minimum finance leases payments	<b>487</b>	922	<b>467</b>	876
Less: future finance charges	<b>(20)</b>	(46)		
Present value of finance leases payables	<b>467</b>	876		
Portion classified as current liabilities	<b>(267)</b>	(409)		
Non-current portion	<b>200</b>	467		

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 22. CONVERTIBLE BONDS

On 27 January 2017, the Company issued 5.5% convertible bonds which are denominated in Hong Kong dollars with an aggregate principal amount of HK\$64,800,000 (the "Convertible Bonds") for cash to the independent third parties.

The Convertible Bonds will be matured on the second anniversary of the date of issue and the conversion price is HK\$0.27 per share subject to anti-dilutive adjustments. Neither the Company nor the holders of the Convertible Bonds may demand early redemption. And the Convertible Bonds bear interests at 5.5% per annum on the outstanding principal amount and would be payable semi-annually in arrears until the Convertible Bonds are converted or matured. Unless previously converted or cancelled, upon maturity of the Convertible Bonds, the Company will pay to the holders of the Convertible Bonds an amount equal to the aggregate of 100% of the principal amount of the Convertible Bonds outstanding and interest accrued and outstanding pursuant to the terms and conditions of the Convertible Bonds.

Details of the Convertible Bonds are set out in the announcements of the Company dated 11 December 2016, 19 January 2017, 27 January 2017 and 6 February 2017.

The Convertible Bonds are treated as a compound financial instrument, and the fair value of the liability component on initial recognition was determined at date of issuance of the Convertible Bonds with reference to a professional valuation performed by a professional independent valuer.

The fair value of the liability component on initial recognition was derived from present value of future cash flows discounted at the effective interest rate, which is estimated with reference to the yields of market instruments with similar credit qualities and time to maturities, and is subject to the adjustment of relevant risk premium and subsequently measured at amortised cost. The residual amount, representing the value of the equity conversion component, was included in convertible bonds equity reserve.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 22. CONVERTIBLE BONDS (Continued)

The Convertible Bonds recognised were calculated as follows:

		HK\$'000	
<b>Equity component</b>			
			64,800
Proceeds at the date of issuance			
Transaction cost attributable to issuance of			
Convertible Bonds allocated to equity component			(365)
Liability component, at the date of issuance			(51,886)
<hr/>			
Equity component at 31 March 2017, 1 April 2017 and 31 March 2018			12,549
<hr/>			
	<i>Note</i>	<b>2018</b>	2017
		<b>HK\$'000</b>	HK\$'000
<hr/>			
<b>Liability component</b>			
At the beginning of the year		<b>52,032</b>	–
At the date of issuance		–	51,886
Transaction cost attributable to issuance of			
Convertible Bonds allocated to liability component		–	(1,468)
Effective interest expense	<i>6</i>	<b>10,299</b>	1,614
Interest paid		<b>(3,564)</b>	–
<hr/>			
<b>Liability component at the end of the year</b>		<b>58,767</b>	52,032
<hr/>			

The effective interest rate of the liability component on initial recognition and the subsequent measure of interest expense on the Convertible Bonds are calculated using effective interest rate of approximately 19% per annum.

## 23. DEFERRED TAX

### Tax losses and deductible temporary differences

The following tax losses and deductible temporary differences have not been recognised as deferred tax assets as it is not considered probable that taxable profits will be available against which the tax losses and deductible temporary differences can be utilised:

	<b>2018</b>	2017
	<b>HK\$'000</b>	HK\$'000
Tax losses	<b>130,563</b>	125,237
Deductible temporary differences	<b>373</b>	250
	<b>130,936</b>	125,487

The Group has tax losses arising in Hong Kong of approximately HK\$105,824,000 (2017: HK\$99,935,000) that may be carried forward indefinitely and subject to the approval by Hong Kong Inland Revenue Department ("IRD") for offsetting against future taxable profits of the companies in which the losses arose.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 23. DEFERRED TAX (Continued)

### Tax losses and deductible temporary differences (Continued)

Regarding to the letters from IRD to the Company dated 9 September 2016 and 30 March 2017, IRD had a dispute on the tax losses claimed by the Company for the assessment years of 2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015 and 2015/2016 and considered certain deductible expenses incurred in those assessment years shall not be eligible for the tax deduction. On 24 January 2017 and 1 December 2017, the Company agreed to withdraw the claim for loss under the assessment years of 2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015 and 2015/2016 in an aggregate amount of approximately HK\$81,829,000. On 27 June 2017 and 2 January 2018, IRD issued a revised statement of loss for the assessment year of 2015/2016 to the Company and agreed the loss carried forward was approximately HK\$23,008,000.

The Group also has tax losses arising in the PRC of approximately HK\$24,739,000 (2017: HK\$25,302,000) that will expire from year 2019 to 2023 (2017: year 2018 to 2022) for offsetting against future taxable profits.

### Withholding tax liability

Pursuant to the PRC Corporate Income Tax Law, withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in the PRC. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. A lower withholding tax rate may be applied if there is a tax treaty between the PRC and the jurisdiction of the foreign investors. For the Group, the applicable rate is 5%. The Group is therefore liable to withholding taxes on dividends distributed by those subsidiaries established in the PRC in respect of earnings generated from 1 January 2008.

No deferred tax has been recognised for withholding taxes that would be payable on the remaining undistributed earnings that are subject to withholding taxes of the Group's subsidiaries established in the PRC. In the opinion of the directors of the Company, the Group is able to control the timing of distribution of earnings and it is not probable that these subsidiaries will distribute such earnings in the foreseeable future. The aggregate amount of temporary differences associated with investments in subsidiaries in the PRC for which deferred tax liabilities have not been recognised totaled approximately HK\$88,704,000 at 31 March 2018 (2017: HK\$63,688,000).

There are no income tax consequences attaching to the payment of dividends by the Company to its shareholders.

## 24. SHARE CAPITAL

	2018 HK\$'000	2017 HK\$'000
<i>Authorised:</i>		
5,000,000,000 ordinary shares of HK\$0.05 each	250,000	250,000

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 24. SHARE CAPITAL (Continued)

	Number of ordinary shares of HK\$0.05 each	Amount HK\$'000
<i>Issued and fully paid:</i>		
At 1 April 2016	1,449,520,000	72,476
Exercise of share options ( <i>note</i> )	2,000,000	100
<b>At 31 March 2017, 1 April 2017 and 31 March 2018</b>	<b>1,451,520,000</b>	<b>72,576</b>

*Note:* During the year ended 31 March 2017, 2,000,000 share options were exercised which resulted in 2,000,000 shares being issued at a price of HK\$0.3 per share.

### Share options

Details of the Company's share option scheme and the share options are included in note 25 to the consolidated financial statements.

## 25. EQUITY COMPENSATION PLANS

### Share Option Scheme

The Company operates a share option scheme adopted by the Company on 17 August 2012 with a resolution passed at the annual general meeting (the "Scheme") for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. The Scheme became effective on 17 August 2012 and, unless otherwise cancelled or amended, would remain in force for 10 years from that date. The maximum number of shares which may be issued upon exercise of all options granted and to be granted under the Scheme is 144,952,000, representing approximately 10% of the shares of the Company in issue as at the date of adoption of the Scheme and the date of approval of these consolidated financial statements.

The maximum number of shares issuable under share options granted to each eligible participant in the Scheme (including both exercised and outstanding options) within any 12-month period is limited to 1% of the shares of the Company in issue. Any grant or further grant of share options in excess of this limit is subject to shareholders' approval in a general meeting.

A grant of share options under the Scheme to a director, chief executive or substantial shareholder of the Company, or to any of their associates, is subject to approval in advance by the independent non-executive directors. In addition, any share options granted to a substantial shareholder or an independent non-executive director of the Company, or to any of their associates, which would result in the shares issued and to be issued, upon exercise of all options already granted and to be granted, to such person in the 12-month period up to and including the date of the grant in excess of 0.1% of the shares of the Company in issue and with an aggregate value (based on the closing price of the Company's shares at the date of grant) in excess of HK\$5 million, are subject to shareholders' approval in advance in a general meeting.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 25. EQUITY COMPENSATION PLANS (Continued)

### Share Option Scheme (Continued)

The offer of a grant of share options under the Scheme may be accepted within 28 days from the date of offer upon payment of a nominal consideration of HK\$10 in total by the grantee. The exercise period of the share options granted is determined by the directors of the Company, save that such a period shall not be more than 10 years from the date of offer of the share options subject to the provisions for early termination as set out in the Scheme. Unless otherwise determined by the directors at their sole discretion, there is no requirement of a minimum period for which an option must be held or a performance target which must be achieved before an option can be exercised.

The exercise price of the share options shall be the highest of (i) the closing price of the Company's shares as stated in the daily quotation sheet of the Stock Exchange on the date of offer of the share options; (ii) the average closing price of the Company's shares as stated in the Stock Exchange's daily quotation sheet for the five trading days immediately preceding the date of offer; and (iii) the nominal value of a share of the Company on the date of offer.

Share options do not confer rights on the holders to dividends or to vote at shareholders' meetings.

On 25 November 2016, the Company granted total of 53,400,000 share options to executive directors and independent non-executive directors of the Company and certain employees of the Group under the Scheme, pursuant to which the Company agreed to grant each of them an option to subscribe for shares of the Company in the consideration of HK\$0.3 each with no fulfilment of the conditions under the Scheme. The grant of the options is part of the incentive offered to the grantees for their past contribution to the diversification of the business of the Group to the food and beverage sector and the supervision of the acquired tea and other food product business.

The following share options were granted and exercised under the Scheme during the year:

	Weighted average exercise price HK\$ per share	Number of share options
At 1 April 2016	0.3	–
Share options granted during the year	0.3	53,400,000
Share options exercised during the year	0.3	(2,000,000)
<b>At 31 March 2017, 1 April 2017 and 31 March 2018</b>		<b>51,400,000</b>

No share options were granted, exercised or lapsed under the Scheme during the year ended 31 March 2018.

During the year ended 31 March 2017, 53,400,000 share options were granted, 2,000,000 share options were exercised and no share options were lapsed under the Scheme.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 25. EQUITY COMPENSATION PLANS (Continued)

### Share Option Scheme (Continued)

The closing price of the Company's share immediately before the date of grant of the options was HK\$0.3 and the estimated fair value of each share under each share option at the date of grant is HK\$0.1323 and HK\$0.0904 for directors and employees respectively, were calculated using Black-Scholes Pricing Model performed by a professional independent valuer, taking into account the terms and conditions upon which the share options were granted. The assumptions used for the calculation are as follows:

	2017
Closing share price at date of grant	HK\$0.3
Exercise price	HK\$0.3
Expected volatility	52.99%
Expected option life	5 years
Expected dividend yield	0%
Risk-free interest rate	1.11%

The variables and assumptions used above were based on the best estimate of an independent professional valuer. The expected volatility was based on the historical daily volatility of the Company's stock price (calculated based on the remaining life of the share options), adjusted for any expected changes to future volatility based on publicly available information. Expected dividends were based on historical dividends. Change in the subjective input assumptions could materially affect the fair value estimate.

There are no vesting period and condition regarding the share option granted. The fair value of the share options granted at the grant date was approximately HK\$6,311,000, of which the Group recognised equity-settled share option expense of approximately HK\$6,311,000 in the consolidated statement of profit or loss for the year ended 31 March 2017.

## 26. RESERVES

The amounts of the Group's reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity of the consolidated financial statements.

### (a) Contributed surplus

The Group's contributed surplus represents the excess of the nominal value of the shares of the subsidiaries acquired pursuant to the Group reorganisation in 2002 over the nominal value of the Company's shares issued in exchange therefor.

### (b) Employee share-based compensation reserve

The employee share-based compensation reserve represents the value of director and employee services in respect of share options granted under the share option as set out in note 25.

### (c) Exchange fluctuation reserve

The exchange fluctuation reserve comprises all foreign exchange differences arising from the translation of foreign operations. The reserve is dealt with in accordance with the accounting policy set out in note 2(v).

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 27. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES

The table below details changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group's consolidated statement of cash flows as cash flows from financing activities.

	<i>Note</i>	<b>Liability component of convertible bonds</b> HK\$'000	<b>Finance leases payables</b> HK\$'000	<b>Due to directors of the Company</b> HK\$'000	<b>Total</b> HK\$'000
At 1 April 2017		52,032	876	3,507	56,415
Financing cash flows					
– Repayments		–	(409)	–	(409)
– Interest paid		(3,564)	(26)	–	(3,590)
– Advances from directors		–	–	243	243
Interest expenses	6	10,299	26	–	10,325
<b>At 31 March 2018</b>		<b>58,767</b>	<b>467</b>	<b>3,750</b>	<b>62,984</b>

## 28. MAJOR NON-CASH TRANSACTION

During the year ended 31 March 2017, the Group entered into a finance lease arrangement in respect of property, plant and equipment with a total capital value at the inception of the lease of approximately HK\$565,000.

## 29. CONTINGENT LIABILITY

The Group did not have any significant contingent liabilities as at 31 March 2018 (2017: Nil).

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 30. OPERATING LEASE ARRANGEMENTS

### (a) As lessor

The Group leases part of its direct sales shop under operating lease arrangements, with leases negotiated for terms for ten years. The terms of the leases generally also require the tenants to pay security deposits and provide for periodic rent adjustment according to the then prevailing market conditions.

At 31 March 2018, the Group had total future minimum lease receivables under non-cancellable operating leases falling due as follows:

	2018 HK\$'000	2017 HK\$'000
Within one year	96	89

### (b) As lessee

The Group leases certain of its office buildings and retail shops in the PRC and offices in Hong Kong under operating lease arrangements. Leases for properties are negotiated for terms ranging from one year to ten years.

At 31 March 2018, the Group had total future minimum lease payments under non-cancellable operating leases falling due as follows:

	2018 HK\$'000	2017 HK\$'000
Within one year	2,635	3,619
In the second to fifth years, inclusive	960	2,749
	3,595	6,368

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 31. RELATED PARTY TRANSACTIONS AND BALANCES

- (a) In addition to those transactions disclosed elsewhere in these consolidated financial statements, the Group had the following material transactions with related companies during the year:

	Notes	2018 HK\$'000	2017 HK\$'000
Sales of tea products to:			
Ideality Group	(i), (vi)	4,530	9,553
Purchases of tea products from:			
雲縣天龍生態茶業有限責任公司 Yunxian Tialong Eco-Tea Company Limited <sup>Ⓐ</sup> ("YTET") <sup>Ⓐ</sup>	(iii), (vi)	303	–
CLRT <sup>Ⓐ</sup>	(iii), (vi)	12,083	16,688
FLRT <sup>Ⓐ</sup>	(iii), (vi)	16,915	20,412
雲南龍潤茶業發展有限公司 Yunnan Longrun Tea Development Company Limited <sup>Ⓐ</sup> ("YLRT") <sup>Ⓐ</sup>	(iv), (vi)	–	103
LRTG <sup>Ⓐ</sup>	(ii), (vi)	14,394	31,736
Purchases of pharmaceutical products from:			
YNLF	(v), (vi)	540	1,094
		<b>44,235</b>	70,033
Rental expense incurred to:			
YLRT	(iv), (vi)	497	484

Notes:

- (i) Ideality Group is beneficially owned as to 85.5% and 14.5% by Dr. Chiu and Mr. Jiao, respectively. Both Dr. Chiu and Mr. Jiao are executive directors and shareholders of the Company, while Dr. Chiu is also a substantial shareholder of the Company.
- (ii) LRTG is beneficially owned as to 97% and 3% by Dr. Chiu and Mr. Jiao, respectively. Both Dr. Chiu and Mr. Jiao are executive directors and shareholders of the Company, while Dr. Chiu is also a substantial shareholder of the Company.
- (iii) The companies are wholly-owned subsidiaries of LRTG.
- (iv) YLRT is beneficially owned as to 77% and 23% by Dr. Chiu and Mr. Jiao, respectively. Both Dr. Chiu and Mr. Jiao are executive directors and shareholders of the Company, while Dr. Chiu is also a substantial shareholder of the Company.
- (v) YNLF is beneficially owned as to 89.4% and 10% by Dr. Chiu and Mr. Jiao, respectively. Both Dr. Chiu and Mr. Jiao are executive directors and shareholders of the Company, while Dr. Chiu is also a substantial shareholder of the Company.
- (vi) The transactions were conducted at rates mutually agreed between the relevant parties.

<sup>Ⓐ</sup> The above transactions in respect of the sales of tea products and the purchases of tea products entered into by the Group during the year ended 31 March 2018 also constituted continuing connected transactions as defined in Chapter 14A of the Listing Rules.

\* Official names of these entities are in Chinese. The English translation of the name is for identification purpose only.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 31. RELATED PARTY TRANSACTIONS AND BALANCES (Continued)

### (b) Outstanding balances with related parties

In addition to those balances disclosed elsewhere in these consolidated financial statements, the Group had the following balances with related parties at the end of the reporting period:

- (i) The amounts due to related companies, 雲南龍潤藥業有限公司 (Yunnan Long Run Pharmaceuticals Company Limited)\* (“YLRP”) and YLRT, are unsecured, non-interest bearing and have no fixed terms of repayment. YLRP is jointly owned by 龍潤藥業集團有限公司 (Long Run Pharmaceuticals Group Limited)\* (“LRGL”) and 雲南龍潤投資有限公司 (Yunnan Longrun Investment Company Limited)\* (“YLI”). LRGL and YLI are beneficially owned as to 90% and 10% by Dr. Chiu and Mr. Jiao, respectively. Both Dr. Chiu and Mr. Jiao are executive directors and shareholders of the Company, while Dr. Chiu is also a substantial shareholder of the Company.
- (ii) The amounts due to directors of the Company are unsecured, interest-free and without fixed terms of repayment.

### (c) Compensation of key management personnel (including directors of the Company) of the Group

	2018 HK\$'000	2017 HK\$'000
Short term employee benefits	10,210	10,701
Equity-settled share option expense	–	6,039
Post-employment benefits	108	105
	<b>10,318</b>	<b>16,845</b>

## 32. FINANCIAL INSTRUMENTS BY CATEGORY

The categories of financial instruments of the Group as at 31 March 2018 and 2017 are as below:

	2018 HK\$'000	2017 HK\$'000
<b>Financial assets</b>		
Loans and receivables	282,494	334,574
Available-for-sale financial assets	7,500	–
	<b>289,994</b>	<b>334,574</b>
<b>Financial liabilities</b>		
Amortised cost	94,542	108,608

\* Official names of these entities are in Chinese. The English translation of the names is for identification purpose only.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 33. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Except for the convertible bonds, the directors of the Company has assessed that the fair values of financial assets and other financial liabilities including cash and cash equivalents, time deposits with original maturities of more than three months, trade receivables, trade payables, loan receivable, deposits and other receivables, other payables and accruals, amounts due to related companies, amounts due to directors of the Company and finance leases payables approximate to their carrying amounts largely due to the short term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The fair value of the debt component of convertible bonds is determined by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The Group's own non-performance risk for convertible bonds as at 31 March 2018 and 2017 was assessed to be insignificant. The fair value of the convertible bonds approximates to their carrying amounts as at 31 March 2018 and 2017.

## 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Group's principal financial instruments comprise cash and short term deposits. The main purpose of these financial instruments is to raise finance for the Group's operations. The Group has various other financial assets and liabilities such as trade and bills receivables and trade payables, which arise directly from its operations.

The main risks arising associated with the Group's financial instruments are credit risk, liquidity risk and market risk (currency risk, interest rate risk). The board of directors reviews and agrees policies for managing each of these risks and they are summarised below.

### Currency risk

The Group's primary foreign currency exposure arises from its distribution of tea and other food products in the PRC. The functional currency of these operating units is RMB and most of the financial instruments (including trade receivables, deposits and other receivables, loan receivable, cash and cash equivalents, trade payables, other payables and accruals and amounts due to related companies) are denominated in RMB. No foreign currency risk has been identified for the financial assets and financial liabilities in the PRC as they were denominated in a currency same as the functional currencies of the operating units.

### Credit risk

The carrying amount of trade receivables included in the consolidated statement of financial position represents the Group's maximum exposure to credit risk in relation to the Group's trade receivables. The Group has a significant concentration of credit risk in relation to trade receivables as the trade receivables due from the five largest customers accounted for 29.8% (2017: 37.2%) of the Group's trade receivables at the end of the reporting period.

As disclosed in note 15, due to adverse operating environment of tea products selling business in the PRC, operating performances of certain customers of the Group were adversely affected and these customers were in financial difficulties so that proportion of long aged trade receivables increased during the year. Accordingly, the Group performs ongoing credit evaluations of its customers' financial conditions and requires no collateral from its customers. The provision for impairment of trade receivables is based upon a review of the expected collectability of all trade receivables and impairment of trade receivables are provided to trade receivables which are overdue over 3 months and without settlements during the reporting period and subsequent to the end of the reporting period.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

### Credit risk (Continued)

With respect to credit risk arising from the other financial assets of the Group, comprising cash and cash equivalents, time deposits with original maturities of more than three months, deposits and other receivables and loan receivable, the Group's exposure to credit risk arises from default of the counterparty, with a maximum exposure being equal to the carrying amounts of these instruments. There is no significant concentration of credit risk within the Group in relation to the other financial assets.

### Liquidity risk

The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial instruments and financial assets (e.g. trade receivables and loan receivable) and projected cash flows from operations.

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of finance leases payables and convertible bonds. In addition, banking facilities have been put in place for contingency purpose.

The following table details Group's remaining contractual maturity for its non-derivative financial liabilities. The table has been drawn up based on the undiscounted cash flows of financial liabilities based on earliest date on which the Group can be required to pay. The maturity dates for non-derivative financial liabilities are based on the agreed repayment dates. The following table includes both interest and principal cash flows:

	2018				Carrying amount at 31/3/2018 HK\$'000
	On demand or within 1 year HK\$'000	In the second year HK\$'000	3 to 5 years HK\$'000	Total undiscounted cash flows HK\$'000	
Trade payables	1,661	–	–	1,661	1,661
Other payables and accruals	29,729	–	–	29,729	29,729
Due to related companies	168	–	–	168	168
Due to directors of the Company	3,750	–	–	3,750	3,750
Finance leases payables	280	124	83	487	467
Convertible bonds and interests (assume no conversion)	68,364	–	–	68,364	58,767
	103,952	124	83	104,159	94,542

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

### Liquidity risk (Continued)

	On demand or within 1 year HK\$'000	In the second year HK\$'000	2017	Total undiscounted cash flows HK\$'000	Carrying amount at 31/3/2017 HK\$'000
			3 to 5 years HK\$'000		
Trade payables	22,383	–	–	22,383	22,383
Other payables and accruals	28,401	–	–	28,401	28,401
Due to related companies	1,409	–	–	1,409	1,409
Due to directors of the Company	3,507	–	–	3,507	3,507
Finance leases payables	435	280	207	922	876
Convertible bonds and interests (assume no conversion)	3,564	68,364	–	71,928	52,032
	59,699	68,644	207	128,550	108,608

### Interest rate risk

The Group does not expose to cash flow interest rate risk arising from its loan receivable, finance leases payables and convertible bonds as the interest rates underlying Group's finance lease payables, loan receivable and convertible bonds are fixed. The Group is exposed to cash flow interest rate risk in relation to its variable-rate bank balances. However, the sensitivity analysis is not prepared as the directors of the Company consider that the exposure of cash flow interest rate risk arising from variable-rate bank balances is insignificant.

## 35. CAPITAL RISK MANAGEMENT

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximise the shareholders' value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the years ended 31 March 2018 and 2017.

The Group monitors capital using a gearing ratio, which is calculated as the total liabilities over the total equity. The gearing ratios as at the end of the reporting periods were as follows:

	2018 HK\$'000	2017 HK\$'000
Total liabilities	113,436	137,404
Total equity	184,210	204,276
Gearing ratio	61.6%	67.3%

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 36. STATEMENT OF FINANCIAL POSITION AND RESERVES OF THE COMPANY

Information about the statement of financial position of the Company at the end of the reporting period is as follows:

	<i>Note</i>	<b>2018</b> <b>HK\$'000</b>	2017 HK\$'000
<b>Non-current assets</b>			
Property, plant and equipment		28	36
Investments in subsidiaries		117,242	117,242
<b>Total non-current assets</b>		<b>117,270</b>	117,278
<b>Current assets</b>			
Prepayments, deposits and other receivables		198	264
Due from subsidiaries		98,241	116,106
Cash and cash equivalents		1	77
<b>Total current assets</b>		<b>98,440</b>	116,447
<b>Current liabilities</b>			
Accruals		11,132	10,931
Due to a subsidiary		6,750	7,186
Due to directors of the Company		2,752	2,520
Convertible bonds	22	58,767	–
<b>Total current liabilities</b>		<b>79,401</b>	20,637
<b>Net current assets</b>		<b>19,039</b>	95,810
<b>Total assets less current liabilities</b>		<b>136,309</b>	213,088
<b>Non-current liability</b>			
Convertible bonds	22	–	52,032
<b>Total non-current liability</b>		–	52,032
<b>Net assets</b>		<b>136,309</b>	161,056
<b>Equity</b>			
Issued share capital		72,576	72,576
Reserves ( <i>note</i> )		63,733	88,480
<b>Total equity</b>		<b>136,309</b>	161,056

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 36. STATEMENT OF FINANCIAL POSITION AND RESERVES OF THE COMPANY (Continued)

Note:

A summary of the Company's reserves is as follows:

	Share premium HK\$'000	Contributed surplus HK\$'000	Employee share-based compensation reserve HK\$'000	Convertible bonds equity reserve HK\$'000	Accumulated losses HK\$'000	Total HK\$'000
At 1 April 2016	252,319	46,999	–	–	(188,126)	111,192
Loss and total comprehensive loss for the year	–	–	–	–	(42,072)	(42,072)
Recognition of equity component of convertible bonds	–	–	–	12,914	–	12,914
Transaction cost attributable to issuance of convertible bonds allocated to equity component	–	–	–	(365)	–	(365)
Exercise of share options	682	–	(182)	–	–	500
Recognition of equity-settled share based payments	–	–	6,311	–	–	6,311
At 31 March 2017 and 1 April 2017	253,001	46,999	6,129	12,549	(230,198)	88,480
Loss and total comprehensive loss for the year	–	–	–	–	(24,747)	(24,747)
<b>At 31 March 2018</b>	<b>253,001</b>	<b>46,999</b>	<b>6,129</b>	<b>12,549</b>	<b>(254,945)</b>	<b>63,733</b>

The Company's contributed surplus represents the excess of the fair value of the shares of the subsidiaries acquired pursuant to the Group reorganisation in 2002 over the nominal value of the Company's shares issued in exchange therefore. Pursuant to Cayman Islands company law, a company may make distributions to its members out of the contributed surplus in certain circumstances.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 37. NEW AND REVISED HKFRSs IN ISSUE BUT NOT YET EFFECTIVE

The Group has not early applied the following new and revised HKFRSs, which have been issued but are not yet effective, in these consolidated financial statements:

HKAS 28 and HKFRS 10 amendments (2011)	Sale or contribution of assets between an investor and its associate or joint venture <sup>4</sup>
HKAS 28 Amendments	Long-term Interests in Associates and Joint Ventures <sup>2</sup>
HKFRS 2 Amendments	Classification and Measurement of Share-based Payment Transactions <sup>1</sup>
HKFRS 4 Amendments	Applying HKFRS 9 Financial Instruments with HKFRS 4 Insurance Contracts <sup>1</sup>
HKFRS 9	Financial Instruments <sup>1</sup>
HKFRS 9 Amendments	Prepayment Features with Negative Compensation <sup>2</sup>
HKFRS 15	Revenue from Contracts with Customers <sup>1</sup>
HKFRS 15 Amendments	Clarification to HKFRS 15 Revenue Contracts with Customers <sup>1</sup>
HKFRS 16	Leases <sup>2</sup>
HKFRS 17	Insurance Contracts <sup>3</sup>
HKAS 40 Amendments	Transfers of Investment Property <sup>1</sup>
HK (IFRIC) – Interpretation 22	Foreign Currency Transactions and Advance Consideration <sup>1</sup>
HK (IFRIC) – Interpretation 23	Uncertainty over Income Tax Treatments <sup>2</sup>
Amendments to HKAS 19	Plan Amendment, Curtailment or Settlement <sup>2</sup>
Amendments to HKFRS 1 and HKAS 28	As part of the Annual Improvements to HKFRSs 2014 – 2016 Cycle <sup>1</sup>
Amendments to HKFRSs	Annual Improvements to HKFRSs 2015 – 2017 Cycle <sup>2</sup>

<sup>1</sup> Effective for annual periods beginning on or after 1 January 2018

<sup>2</sup> Effective for annual periods beginning on or after 1 January 2019

<sup>3</sup> Effective for annual periods beginning on or after 1 January 2021

<sup>4</sup> The amendments were original intended to be effective for annual periods beginning on or after 1 January 2016. The effective date has now been deferred. Early application of the amendments continues to be permitted.

Except for the new and amendments to HKFRSs and interpretations mentioned below, the directors of the Company anticipate that the application of all other new and amendments to HKFRSs and Interpretations will have no material impact on the consolidated financial statements in the foreseeable future.

### HKFRS 9 “Financial Instruments”

HKFRS 9 introduces new requirements for the classification and measurement of financial assets, financial liabilities, general hedge accounting and impairment requirements for financial assets.

Key requirements of HKFRS 9 which are relevant to the Group are:

In relation to the impairment of financial assets, HKFRS 9 requires an expected credit loss model, as opposed to an incurred credit loss model under HKAS 39. The expected credit loss model requires an entity to account for expected credit losses and changes in those expected credit losses at each reporting date to reflect changes in credit risk since initial recognition. In other words, it is no longer necessary for a credit event to have occurred before credit losses are recognised. Such requirement is expected to have effect to the impairment assessment of accounts receivables.

Listed equity securities classified as available-for-sale investments carried at fair value are qualified for the designation as measured at fair value through other comprehensive income (“FVTOCI”) under HKFRS 9, however, the Group plans not to elect the option for the designation and will measure these securities at fair value with subsequent fair value gains or losses to be recognised in profit or loss. Upon initial application of HKFRS 9, assets revaluation reserve (if any) related to these available-for-sale investments will be transferred to retained profits at 1 April 2018.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 37. NEW AND REVISED HKFRSs IN ISSUE BUT NOT YET EFFECTIVE (Continued)

### HKFRS 15 “Revenue from Contracts with Customers”

HKFRS 15 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. HKFRS 15 will supersede the current revenue recognition guidance including HKAS 18 Revenue, HKAS 11 Construction Contracts and the related Interpretations when it becomes effective.

The core principle of HKFRS 15 is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Specifically, HKFRS 15 introduces a 5-step approach to revenue recognition:

- Step 1: Identify the contract(s) with a customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognise revenue when (or as) the entity satisfies a performance obligation

Under HKFRS 15, an entity recognises revenue when (or as) a performance obligation is satisfied, i.e. when ‘control’ of the goods or services underlying the particular performance obligation is transferred to the customer. Far more prescriptive guidance has been added in HKFRS 15 to deal with specific scenarios. Furthermore, extensive disclosures are required by HKFRS 15.

In 2016, the HKICPA issued Clarifications to HKFRS 15 in relation to the identification of performance obligations, principal versus agent considerations, as well as licensing application guidance.

The directors of the Company anticipate that the application of HKFRS 15 in the future may result in more disclosures, however, the directors of the Company do not anticipate that the application of HKFRS 15 will have a material impact on the timing and amounts of revenue recognised in the respective reporting periods.

### HKFRS 16 “Leases”

HKFRS 16 introduces a comprehensive model for the identification of lease arrangements and accounting treatments for both lessors and lessees. HKFRS 16 will supersede HKAS 17 Leases and the related interpretations when it becomes effective.

HKFRS 16 distinguishes lease and service contracts on the basis of whether an identified asset is controlled by a customer. Distinctions of operating leases and finance leases are removed for lessee accounting, and is replaced by a model where a right-of-use asset and a corresponding liability have to be recognised for all leases by lessees, except for short-term leases and leases of low value assets.

The right-of-use asset is initially measured at cost and subsequently measured at cost (subject to certain exceptions) less accumulated depreciation and impairment losses, adjusted for any re-measurement of the lease liability. The lease liability is initially measured at the present value of the lease payments that are not paid at that date. Subsequently, the lease liability is adjusted for interest and lease payments, as well as the impact of lease modifications, amongst others. Under the HKFRS 16, lease payments in relation to lease liability will be allocated into a principal and an interest portion which will be presented as financing cash flows.

# Notes to the Consolidated Financial Statements (Continued)

For the year ended 31 March 2018

## 37. NEW AND REVISED HKFRSs IN ISSUE BUT NOT YET EFFECTIVE (Continued)

### HKFRS 16 “Leases” (Continued)

Under HKAS 17, the Group has already recognised an asset and a related finance lease liability for finance lease arrangement. The application of HKFRS 16 may result in potential changes in classification of these assets depending on whether the Group presents right-of-use assets separately or within the same line item at which the corresponding underlying assets would be presented if they were owned.

In contrast to lessee accounting, HKFRS 16 substantially carries forward the lessor accounting requirements in HKAS 17, and continues to require a lessor to classify a lease either as an operating lease or a finance lease.

Furthermore, extensive disclosures are required by HKFRS 16.

As at 31 March 2018, the Group has non-cancellable operating lease commitments as disclosed in note to consolidated financial statements. A preliminary assessment indicates that approximately HK\$24,700,000 out of these arrangements will meet the definition of a lease under HKFRS 16, and hence the Group will recognise a right-of-use asset and a corresponding liability in respect of all these leases unless they qualify for low value or short-term leases upon the application of HKFRS 16. The findings from the preliminary assessment are subject to change.

Furthermore, the application of new requirements may result changes in measurement, presentation and disclosure as indicated above.

## 38. EVENT AFTER THE REPORTING PERIOD

Subsequent to 31 March 2018, on 30 May 2018 and 14 August 2018, the Group disposed of 8,000,000 and 7,000,000 out of 15,000,000 of its listed equity securities classified as available-for-sale financial assets respectively in the open market with the aggregate fair value amounting to HK\$7,500,000 as at 31 March 2018 for an aggregate consideration of approximately HK\$12,891,000.

## Five Year Financial Summary

A summary of the results and assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the published audited consolidated financial statements, is set out below:

### RESULTS

	2018 HK\$'000	Year ended 31 March			
		2017 HK\$'000	2016 HK\$'000	2015 HK\$'000	2014 HK\$'000
<b>Revenue</b>	<b>81,670</b>	123,690	217,659	256,439	286,514
<b>(Loss)/profit before tax</b>	<b>(33,887)</b>	(32,167)	4,799	(207,441)	15,138
Income tax (expense)/credit	(15)	(264)	(2,385)	3,564	(230)
<b>(Loss)/profit for the year</b>	<b>(33,902)</b>	(32,431)	2,414	(203,877)	14,908
Attributable to:					
Owners of the Company	<b>(33,902)</b>	(32,431)	2,414	(203,877)	14,908
Non-controlling interests	–	–	–	–	–
	<b>(33,902)</b>	(32,431)	2,414	(203,877)	14,908

### ASSETS AND LIABILITIES

	2018 HK\$'000	As at 31 March			
		2017 HK\$'000	2016 HK\$'000	2015 HK\$'000	2014 HK\$'000
<b>Total assets</b>	<b>297,646</b>	341,680	324,424	361,267	591,623
<b>Total liabilities</b>	<b>(113,436)</b>	(137,404)	(98,272)	(119,729)	(146,768)
	<b>184,210</b>	204,276	226,152	241,538	444,855